EP0248594A2 - Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same - Google Patents
Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same Download PDFInfo
- Publication number
- EP0248594A2 EP0248594A2 EP87304720A EP87304720A EP0248594A2 EP 0248594 A2 EP0248594 A2 EP 0248594A2 EP 87304720 A EP87304720 A EP 87304720A EP 87304720 A EP87304720 A EP 87304720A EP 0248594 A2 EP0248594 A2 EP 0248594A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- methoxyphenyl
- chlorophenyl
- pyrazolyl
- lower alkyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000002194 synthesizing effect Effects 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- -1 lower alkythio Chemical group 0.000 claims description 100
- 150000001875 compounds Chemical class 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 230000037361 pathway Effects 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010061218 Inflammation Diseases 0.000 claims description 13
- MBANUMPQBHIYBV-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanal Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC=O)=N1 MBANUMPQBHIYBV-UHFFFAOYSA-N 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 10
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 102000003820 Lipoxygenases Human genes 0.000 claims description 9
- 108090000128 Lipoxygenases Proteins 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- SRLOOKOZKNSJDW-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCO)=N1 SRLOOKOZKNSJDW-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- VPBMQRZRSXKBDV-UHFFFAOYSA-N n-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propylidene]hydroxylamine Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC=NO)=N1 VPBMQRZRSXKBDV-UHFFFAOYSA-N 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- HHRIGSMDZUKIEQ-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propan-1-amine Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCN)=N1 HHRIGSMDZUKIEQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 claims description 4
- ZUBMGVBDXVBCMT-UHFFFAOYSA-N 3-[1-(4-bromophenyl)-5-(4-chlorophenyl)pyrazol-3-yl]propan-1-ol Chemical compound C=1C=C(Br)C=CC=1N1N=C(CCCO)C=C1C1=CC=C(Cl)C=C1 ZUBMGVBDXVBCMT-UHFFFAOYSA-N 0.000 claims description 3
- NNOXNMOPTSCPHG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-cyclohexyl-n-hydroxypropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(O)C2CCCCC2)=N1 NNOXNMOPTSCPHG-UHFFFAOYSA-N 0.000 claims description 3
- IGWHYOSIKLFYMU-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-ethyl-n-hydroxypropanamide Chemical compound C=1C=C(OC)C=CC=1N1N=C(CCC(=O)N(O)CC)C=C1C1=CC=C(Cl)C=C1 IGWHYOSIKLFYMU-UHFFFAOYSA-N 0.000 claims description 3
- IQQZMKSTSMYAKU-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-hydroxy-n-phenylpropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(O)C=2C=CC=CC=2)=N1 IQQZMKSTSMYAKU-UHFFFAOYSA-N 0.000 claims description 3
- GHPBIETXSUATQO-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-hydroxy-n-propan-2-ylpropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(O)C(C)C)=N1 GHPBIETXSUATQO-UHFFFAOYSA-N 0.000 claims description 3
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- LSZGJMGLSIYRMX-UHFFFAOYSA-N n-tert-butyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-hydroxypropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(O)C(C)(C)C)=N1 LSZGJMGLSIYRMX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- XEQZOYPALXWXKZ-UHFFFAOYSA-N 2-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoylamino]acetic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)NCC(O)=O)=N1 XEQZOYPALXWXKZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- GKDAUTZWCZFISK-UHFFFAOYSA-N 3-[1-(4-methoxyphenyl)-5-[4-(trifluoromethyl)phenyl]pyrazol-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)C(F)(F)F)=CC(CCCO)=N1 GKDAUTZWCZFISK-UHFFFAOYSA-N 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 125000005646 oximino group Chemical group 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 abstract description 20
- 238000002360 preparation method Methods 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 132
- 239000000243 solution Substances 0.000 description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 56
- 239000007787 solid Substances 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 229910001868 water Inorganic materials 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 38
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 238000005481 NMR spectroscopy Methods 0.000 description 35
- 238000003756 stirring Methods 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 238000002425 crystallisation Methods 0.000 description 19
- 230000008025 crystallization Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 239000003480 eluent Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 150000001299 aldehydes Chemical class 0.000 description 13
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 7
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- CQFYWWGRHXVJDX-UHFFFAOYSA-N n-hydroxy-3-[1-(4-methoxyphenyl)-4-methyl-5-(4-methylphenyl)pyrazol-3-yl]-n-methylpropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(C)=CC=2)=C(C)C(CCC(=O)N(C)O)=N1 CQFYWWGRHXVJDX-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000003810 Jones reagent Substances 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- SDRWJLDMTCKDSU-WEVVVXLNSA-N 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-[(e)-4-phenylbut-3-enyl]pyrazole Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CC\C=C\C=2C=CC=CC=2)=N1 SDRWJLDMTCKDSU-WEVVVXLNSA-N 0.000 description 3
- JALGKJZTINOYKA-UHFFFAOYSA-N 5-methyl-6-(4-methylphenyl)-4,6-dioxohexanoic acid Chemical compound OC(=O)CCC(=O)C(C)C(=O)C1=CC=C(C)C=C1 JALGKJZTINOYKA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 150000002442 hydroxyeicosatetraenoic acids Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- WJXQDDRGIIWWKT-UHFFFAOYSA-M (4-methoxycarbonylphenyl)-triphenylphosphanium;chloride Chemical compound [Cl-].C1=CC(C(=O)OC)=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WJXQDDRGIIWWKT-UHFFFAOYSA-M 0.000 description 2
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- XFRBXZCBOYNMJP-UHFFFAOYSA-N 2,2,6-trimethyl-1,3-dioxin-4-one Chemical compound CC1=CC(=O)OC(C)(C)O1 XFRBXZCBOYNMJP-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NYHDFYNBHAGCBJ-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]ethanamine Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCN)=N1 NYHDFYNBHAGCBJ-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical group NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- GUGQQGROXHPINL-UHFFFAOYSA-N 2-oxobutanoyl chloride Chemical compound CCC(=O)C(Cl)=O GUGQQGROXHPINL-UHFFFAOYSA-N 0.000 description 2
- UZNXQISRALRROE-UHFFFAOYSA-N 3-[1-(4-methoxyphenyl)-4-methyl-5-(4-methylphenyl)pyrazol-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(C)=CC=2)=C(C)C(CCC(O)=O)=N1 UZNXQISRALRROE-UHFFFAOYSA-N 0.000 description 2
- WJBRUZVPABBUDO-UHFFFAOYSA-N 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)pyrazol-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(C)=CC=2)=CC(CCCO)=N1 WJBRUZVPABBUDO-UHFFFAOYSA-N 0.000 description 2
- OKQBOJVHIPIDPE-UHFFFAOYSA-N 3-[4-bromo-5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=C(Br)C(CCC(O)=O)=N1 OKQBOJVHIPIDPE-UHFFFAOYSA-N 0.000 description 2
- CDZCFDNXJSKKPJ-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n'-hydroxypropanimidamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(N)=NO)=N1 CDZCFDNXJSKKPJ-UHFFFAOYSA-N 0.000 description 2
- CGRSCFNOTZUXCX-UHFFFAOYSA-N 4,6-dioxohexanoic acid Chemical compound OC(=O)CCC(=O)CC=O CGRSCFNOTZUXCX-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical group NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- BBOKPRXZLKOACW-UHFFFAOYSA-N N-[4-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]butan-2-ylideneamino]-1,3-thiazol-2-amine Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(C)=NNC=2SC=CN=2)=N1 BBOKPRXZLKOACW-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical class ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UXJUGHOAVDCYGL-UHFFFAOYSA-N [3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoyl-methylamino] 2-chloroacetate Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)OC(=O)CCl)=N1 UXJUGHOAVDCYGL-UHFFFAOYSA-N 0.000 description 2
- YVPMAKCTMHWFSP-UHFFFAOYSA-N [acetyl-[2-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoyl]amino] acetate Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(C)C(=O)N(OC(C)=O)C(C)=O)=N1 YVPMAKCTMHWFSP-UHFFFAOYSA-N 0.000 description 2
- 150000008062 acetophenones Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- USFRYJRPHFMVBZ-UHFFFAOYSA-M benzyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 USFRYJRPHFMVBZ-UHFFFAOYSA-M 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- DDBGMLLDJSHYKO-UHFFFAOYSA-N ethyl 2-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propyl-hydroxyamino]-2-oxoacetate Chemical compound C=1C=C(OC)C=CC=1N1N=C(CCCN(O)C(=O)C(=O)OCC)C=C1C1=CC=C(Cl)C=C1 DDBGMLLDJSHYKO-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 2
- 230000000917 hyperalgesic effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- ULLDUBJDUFBFAO-UHFFFAOYSA-N n-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propyl]-n-hydroxyacetamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCN(O)C(C)=O)=N1 ULLDUBJDUFBFAO-UHFFFAOYSA-N 0.000 description 2
- RLQARDDIEBTHTR-UHFFFAOYSA-N n-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propyl]acetamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCNC(C)=O)=N1 RLQARDDIEBTHTR-UHFFFAOYSA-N 0.000 description 2
- PDIYRHZFIAJXOL-UHFFFAOYSA-N n-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propyl]hydroxylamine Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCNO)=N1 PDIYRHZFIAJXOL-UHFFFAOYSA-N 0.000 description 2
- LPEHVMLFHZLPJJ-UHFFFAOYSA-N n-acetyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-hydroxypropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(O)C(C)=O)=N1 LPEHVMLFHZLPJJ-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- AQXMGCYWHTXCNT-UHFFFAOYSA-M sodium;3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoate Chemical compound [Na+].C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC([O-])=O)=N1 AQXMGCYWHTXCNT-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical group C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- SMLQYLWIEBFFKG-UHFFFAOYSA-N (3,4-dimethoxyphenyl)hydrazine Chemical group COC1=CC=C(NN)C=C1OC SMLQYLWIEBFFKG-UHFFFAOYSA-N 0.000 description 1
- BTWNEJOURYOHME-UHFFFAOYSA-N 1,3-thiazol-2-ylhydrazine Chemical compound NNC1=NC=CS1 BTWNEJOURYOHME-UHFFFAOYSA-N 0.000 description 1
- ZHOKXGPMVKBAKR-UHFFFAOYSA-N 1-(4-chlorophenyl)-6-hydroxyhexane-1,3-dione Chemical compound OCCCC(=O)CC(=O)C1=CC=C(Cl)C=C1 ZHOKXGPMVKBAKR-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical group CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical class C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical group CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical group NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- MEOVPKDOYAIVHZ-UHFFFAOYSA-N 2-chloro-1-(1-methylpyrrol-2-yl)ethanol Chemical compound CN1C=CC=C1C(O)CCl MEOVPKDOYAIVHZ-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006149 2-ethylbutyl sulfonyl group Chemical group 0.000 description 1
- CWJSCIWGSUCULS-UHFFFAOYSA-N 2-hydroperoxyicosa-2,4,6,8-tetraenoic acid Chemical class CCCCCCCCCCCC=CC=CC=CC=C(OO)C(O)=O CWJSCIWGSUCULS-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- GUROUCGDWJDDDH-UHFFFAOYSA-N 3-[4-bromo-5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=C(Br)C(CCCO)=N1 GUROUCGDWJDDDH-UHFFFAOYSA-N 0.000 description 1
- KFGBAEAAMHEQRO-UHFFFAOYSA-N 3-[4-chloro-5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propan-1-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=C(Cl)C(CCCO)=N1 KFGBAEAAMHEQRO-UHFFFAOYSA-N 0.000 description 1
- RSKOHVIFELRQID-UHFFFAOYSA-N 3-[5-(3,4-dichlorophenyl)-1-(3,4-dimethoxyphenyl)pyrazol-3-yl]propan-1-ol Chemical compound C1=C(OC)C(OC)=CC=C1N1C(C=2C=C(Cl)C(Cl)=CC=2)=CC(CCCO)=N1 RSKOHVIFELRQID-UHFFFAOYSA-N 0.000 description 1
- WHDBWLWLLMCWCA-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n,n-diethylpropanamide Chemical compound C=1C=C(OC)C=CC=1N1N=C(CCC(=O)N(CC)CC)C=C1C1=CC=C(Cl)C=C1 WHDBWLWLLMCWCA-UHFFFAOYSA-N 0.000 description 1
- IFLPKBSWRBODAH-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-n-hydroxypropanamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)NO)=N1 IFLPKBSWRBODAH-UHFFFAOYSA-N 0.000 description 1
- OKOMLJAUMRMPCK-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanenitrile Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC#N)=N1 OKOMLJAUMRMPCK-UHFFFAOYSA-N 0.000 description 1
- JWWITSKUTWOSQS-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(O)=O)=N1 JWWITSKUTWOSQS-UHFFFAOYSA-N 0.000 description 1
- ONJKSBUQLQYPHX-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propyl 3-oxobutanoate Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCCOC(=O)CC(C)=O)=N1 ONJKSBUQLQYPHX-UHFFFAOYSA-N 0.000 description 1
- WXVPSKFHMWDFPT-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-phenylpyrazol-3-yl]propanoic acid Chemical compound C=1C=CC=CC=1N1N=C(CCC(=O)O)C=C1C1=CC=C(Cl)C=C1 WXVPSKFHMWDFPT-UHFFFAOYSA-N 0.000 description 1
- NSUVFMRPQWBGKZ-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)-1-phenylpyrazol-3-yl]propyl acetate Chemical compound C=1C=CC=CC=1N1N=C(CCCOC(=O)C)C=C1C1=CC=C(Cl)C=C1 NSUVFMRPQWBGKZ-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- UNZZKJZWWKBXDK-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazol-5-ol Chemical class OC1CC=NN1 UNZZKJZWWKBXDK-UHFFFAOYSA-N 0.000 description 1
- CTZKFAMYDIEAFX-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-2-methylbutan-2-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(C)(C)O)=N1 CTZKFAMYDIEAFX-UHFFFAOYSA-N 0.000 description 1
- XNJPCDXGVKUDJN-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]butan-2-ol Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(C)O)=N1 XNJPCDXGVKUDJN-UHFFFAOYSA-N 0.000 description 1
- BQHNTBIILYCNNA-UHFFFAOYSA-N 4-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]butan-2-one Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(C)=O)=N1 BQHNTBIILYCNNA-UHFFFAOYSA-N 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- YFNYMVRZQYBOPV-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(3-methoxypropyl)pyrazole Chemical compound C=1C=C(OC)C=CC=1N1N=C(CCCOC)C=C1C1=CC=C(Cl)C=C1 YFNYMVRZQYBOPV-UHFFFAOYSA-N 0.000 description 1
- WBLKFNFZURNECM-PFONDFGASA-N 5-(4-chlorophenyl)-3-[(z)-hexadec-3-enyl]-1-(4-methoxyphenyl)pyrazole Chemical compound C=1C=C(OC)C=CC=1N1N=C(CC\C=C/CCCCCCCCCCCC)C=C1C1=CC=C(Cl)C=C1 WBLKFNFZURNECM-PFONDFGASA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 0 C**(CCCC1=**(C(CC2)CCC2O)C(C2C=CC(N)=CC2)=C1)N Chemical compound C**(CCCC1=**(C(CC2)CCC2O)C(C2C=CC(N)=CC2)=C1)N 0.000 description 1
- PCQABCAZWQTQDN-UHFFFAOYSA-N C=1C=CC=CC=1P(C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 PCQABCAZWQTQDN-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical group C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010017969 Gastrointestinal inflammatory conditions Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Chemical group 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- DLGYNVMUCSTYDQ-UHFFFAOYSA-N azane;pyridine Chemical group N.C1=CC=NC=C1 DLGYNVMUCSTYDQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- GHDLZGOOOLEJKI-UHFFFAOYSA-N benzenesulfonylurea Chemical compound NC(=O)NS(=O)(=O)C1=CC=CC=C1 GHDLZGOOOLEJKI-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- CMMUKUYEPRGBFB-UHFFFAOYSA-L dichromic acid Chemical compound O[Cr](=O)(=O)O[Cr](O)(=O)=O CMMUKUYEPRGBFB-UHFFFAOYSA-L 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical group CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- NSIFOGPAKNSGNW-UHFFFAOYSA-M dodecyl(triphenyl)phosphonium bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCCCC)C1=CC=CC=C1 NSIFOGPAKNSGNW-UHFFFAOYSA-M 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical group Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical group [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical group [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- NJMYRCBQAMWFNA-HWKANZROSA-N methyl 4-[(e)-4-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]but-1-enyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1\C=C\CCC1=NN(C=2C=CC(OC)=CC=2)C(C=2C=CC(Cl)=CC=2)=C1 NJMYRCBQAMWFNA-HWKANZROSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- RSIPQHOWTCNEBI-UHFFFAOYSA-N n-hydroxypropanamide Chemical group CCC(=O)NO RSIPQHOWTCNEBI-UHFFFAOYSA-N 0.000 description 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical group CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DCSATTBHEMKGIP-UHFFFAOYSA-N n-tert-butylhydroxylamine;hydron;chloride Chemical compound Cl.CC(C)(C)NO DCSATTBHEMKGIP-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical group CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- JCJNESZDNINBSA-UHFFFAOYSA-N phenyl(1H-pyrazol-5-yl)methanimine Chemical class C=1C=CC=CC=1C(=N)C=1C=CNN=1 JCJNESZDNINBSA-UHFFFAOYSA-N 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical class Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical group Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- ZPASEBVQANBCFC-UHFFFAOYSA-N propanoic acid;1h-pyrazole Chemical class CCC(O)=O.C=1C=NNC=1 ZPASEBVQANBCFC-UHFFFAOYSA-N 0.000 description 1
- GYPZFDNQZCSGND-UHFFFAOYSA-N propanoic acid;hydrate Chemical compound O.CCC(O)=O GYPZFDNQZCSGND-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- QGUALMNFRILWRA-UHFFFAOYSA-M tolmetin sodium Chemical compound [Na+].C1=CC(C)=CC=C1C(=O)C1=CC=C(CC([O-])=O)N1C QGUALMNFRILWRA-UHFFFAOYSA-M 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- XYHPHHAYGJJBHW-UHFFFAOYSA-M triphenyl(tridecyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCCCCCCCCCC)C1=CC=CC=C1 XYHPHHAYGJJBHW-UHFFFAOYSA-M 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/88—Unsaturated compounds containing keto groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to substituted pyrazole derivatives, and particularly to 1,5-diaryl 3-substituted-pyrazoles that are pharmacologically active in alleviating inflammation, asthma, hypersensitivity, myocardial ischemia, dermatological conditions such as psoriasis, dermatitis and gastrointestinal inflammatory conditions such as inflammatory bowel syndromes, and to a method for synthesizing those pyrazole derivatives.
- Nonsteroidal anti-inflammatory drugs such as indomethacin, naproxen, ibuprofen, tolectin, fenoprofen and the like have generally been shown to attenuate the biosynthesis of prostaglandins by inhibiting the activity of the enzyme cyclooxygenase.
- the prostaglandin end-products of the cyclooxygenase pathway are responsible for many of the early signs of inflammation including hyperalgesia, increases in vascular permeability leading to edema, and pyrexia.
- the activity and potency of the NSAID's in reducing these signs and symptoms is, for the most part, correlated with their ability to inhibit prostaglandin biosynthesis.
- the other major pathway of arachidonic acid metabolism is the lipoxygenase pathway.
- Lipoxygenase products of arachidonate metabolism, the leukotrienes, hydroxyeicosatetraenoic acids (HETES) and hydroperoxyeicosatetraenoic acids (HEPTES) have been shown or implicated to be involved in disease states including acute and chronic inflammation, arthritis, allergic and other hypersensitivity disorders, dermatological diseases such as psoriasis, acne, atopic dermatitis, contact sensitivity, eczema and others, cardiovascular disorders secondary to myocardial ischemia or infarction, thromboembolism or vasculitis or platelet aggregation, and hyperalgesic disorders, gynecological disorders such as dysmenorrhea, ocular inflammation, sperm motility or function, and others.
- Leukotriene B4 (LTB4), another product of the lipoxygenase pathway, as well as HETES and HPETES can mediate induction of other phlogistic substances such as thromboxanes and prostacyclin, is chemotactic to inflammatory cells and is hyperalgesic. Many of these mediators have been identified in skin, lungs, coronary circulation, eyes, gastrointestinal tract and other organs, and in the synovial fluid of rheumatoid arthritic patients. In chronic inflammatory conditions such as rheumatoid arthritis, it is believed to be the chronic influx of leukocytes, probably mediated by LTB4, that is the eventual cause of joint erosion.
- Pharmacologically active compounds that can inhibit both enzyme pathways at similar concentrations (dual inhibitors) provide a more complete relief for patients suffering from arthritis, hypersensitivity, dermatological, cardiovascular, gastrointestinal, ocular, and gynecological disorders than present drugs that inhibit one pathway, but not the other as is the case for usually used NSAID's that are predominantly inhibitors of the cyclooxygenase (prostaglandin synthesis) pathway.
- Vereshchagin et al., Zh. Org. Khim., 7 :907-912 (1971) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles.
- the 3-substituents were reported to be alkoxy alkylene in which the alkoxy radical was methoxy or phenoxy and the alkylene was methylene or isopropylene, while the 1,5-diaryl radicals were unsubstituted phenyl.
- the present invention contemplates 1,5-diaryl-3-substituted pyrazoles, their use and a method of their synthesis.
- the compounds of the present invention are pharamacologically active in alleviating inflammation, and inhibit the cyclooxygenase enzyme pathway, the lipoxygenase enzyme pathway, or preferably both pathways.
- the invention contemplates a substituted pyrazole compound having a structure that conforms to the formula wherein R1, R2, R3 and R4 are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, amino, acetamido, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, ⁇ -trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R1, R2 or R3, R4 taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group; R is a straight, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms; Y is hydrogen, bromo, chloro or lower alkyl having 1-4 carbon atoms; and X is selected from the group consisting of carboxy, carbolow
- R2 and R4 are hydrogen, and R1 and R3 are selected from the group consisting of halo, trifluroromethyl, lower alkyl and lower alkoxy, especially methoxy.
- R preferably contains two carbon atoms.
- the X be hydroxyloweralkyl, carboxy, a hydroxamic acid or a N alkyl hydroxamic acid; i.e., that X be C(O)NR6R7 where R6 is hydroxy and R7 is hydrogen or lower alkyl or a N-alkyl hydroxamic acid; i.e. that x is -C(O)NR6R7 wheren R6 is hydroxy or -OC(O)CH2Z where Z is dialkylamino or -CH2CO2H and R7 is hydrogen or lower alkyl.
- the present invention also contemplates a pharmaceutical composition that comprises an anti-inflammatory amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier.
- the dose may be administered by topical, p.o., parenteral or aerosol routes.
- that substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and the lipoxygenase pathways in the amount present in the composition, when the composition is introduced into a mammal.
- That method comprises administering to that mammal a pharmaceutical composition that includes as the active ingredient an effective amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier for topical, oral, parenteral and aerosol administration.
- a method for synthesizing a 1,5-diaryl-3-(omega-substituted lower alkyl)pyrazole is also contemplated.
- an aryl hydrazine or its acid addition salt is reacted with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain.
- a polar solvent is used that is substantially inert to the reaction conditions, as is the omega-substituent of the alkyl 1,3-dione.
- the resulting 1,5-diaryl-3-(omega lower alkyl substituted) pyrazole is thereafter preferably recovered, although it can be utilized in the form of its synthesis (crude form), as for further syntheses.
- Particularly preferred alkyl-1,3-dione derivatives contain 6 carbons in the alkyl chain and contain a hydroxy group as the omega-substituent.
- the present invention provides several benefits and advantages.
- a particular benefit of the invention is that it provides pharmacologically active compounds that are useful in treating inflammatory conditions.
- a particular advantage of the present invention is that its synthetic method provides relatively high yields of 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole compounds.
- Another benefit of the present invention is that some of its pharmacologically active compounds inhibit the cyclooxygenase enzyme pathway, thereby providing a further means for studying that biological process.
- Another advantage of the present invention is that some of its pharmacologically active compounds inhibit the lipoxygenase enzyme pathway, thereby providing a further means for studying that biological process.
- 1,5-Diaryl-3-substituted pyrazole compounds pharmaceutical compositions containing a substituted pyrazole compound as an active ingredient, a method of treating a mammal exhibiting an inflammatory condition and a method of synthesizing the substituted pyrazole compound are contemplated herein.
- R1, R2, R3 and R4 are substituents on phenyl rings that substitute for hydrogen atoms at positions 1 and 5 of the pyrazole ring. It is preferred that at least one of R1 and R2, and one of R3 and R4 be substituted at the 4-positions of their respective phenyl rings.
- R1, R2, R3 and R4 radicals and the X group can be a "lower” alkyl, “lower” alkoxy and the like.
- Groups and radicals referred to as “lower” denote that they possess 1 to about 6 carbon atoms. The same is true for “lower” groups and radicals that are sustituents of the "lower” groups and radicals enumerated.
- Lower alkyl radicals include, for example, methyl, ethyl, propyl, isopropyl, n -butyl, sec -butyl, t -butyl, n -pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n -hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, octyl and the like.
- Lower alkoxy radicals are oxygen ethers formed from a before-described lower alkyl group.
- Exemplary radicals include methoxy, ethoxy, propoxy, isopropoxy, n -butoxy, and the like.
- Lower alkylthio radicals of R1,R2,R3 and R4 are sulfide ethers and are thus analogous to the oxygen ethers described above.
- Halo radicals preferably include chloro and bromo, as well as fluoro and iodo.
- Lower alkylsulfonyl radicals contain a before-described lower alkyl radical bonded to an SO2 moiety that is itself also bonded to a phenyl ring.
- Exemplary lower alkylsulfonyl radicals thus include methylsulfonyl, ethylsulfonyl, 2-ethylbutylsulfonyl and the like.
- An omega-trifluoromethyl lower alkoxy radical is a lower alkoxy radical as before described that additionally includes a trifluoromethyl group at a position farthest on the alkyl chain from the place of bonding to the phenyl ring.
- Exemplary of such radicals are the 2,2,2-trifluoroethoxy.
- Naphthyl and substituted naphthyl radicals can replace an aryl group herein at either the 1- or 2-positions to provide 1-naphthyl or 2-napththyl substituents, respectfully.
- Substituents on the naphthyl radicals can be any of those described herein as being useful aryl substituents.
- Exemplary substituted 1- and 2-naphthyls include 6-methoxy-2-naphthyl and the like.
- Lower alkyl carboxy radicals are the before-described lower alkyl radicals that further include a carboxy group.
- Exemplary lower alkyl carboxy radicals include carboxymethyl, 2-carboxyhexyl and the like.
- Lower alkyl lower alkoxy carbonyl radicals are lower alkyl esters of lower alkyl carboxy radicals.
- Exemplary lower alkyl lower alkoxy carbonyl radicals include 3-isopropoxycarbonylpropyl, 4-hexyloxycarbonylpentyl and the like.
- a lower alkyl carbonyl radical contains a carbonyl group, a total of up to six carbon atoms, and with the portion of R to which it is linked, forms a ketone at the R/X junction.
- Exemplary lower alkyl carbonyl radicals include acetyl, propionyl 2-methylpropionyl, pentoyl and the like, which can also be named methyl carbonyl, ethyl carbonyl, isopropylcarbonyl and butylcarbonyl, respectively.
- Radicals in which X is C(O)-R5 where in R5 is lower alkoxy are carboxylic esters. These esters are preferably named by considering R-X to be a single substituent entity. Exemplary R5 lower alkoxy groups are as before described, although methoxy and ethoxy are preferred. When R5 is NR6R7 and ONR8R9, it is also useful to consider R-X as a substituent entity.
- Lower hydroxy alkyl radicals of R6 and R7 are preferably 2-hydroxyethyl and 2-hydroxypropyl. Additionally useful lower hydroxy alkyl radicals include 4-hydroxybutyl and the like.
- Substituted phenyl radicals that can comprise NR6R7 are the same as the substituted aryl groups described before wherein R1, R2, R3 and R4 comprise the substituents.
- Pyridyl radicals are derivatives of pyridine and can be bonded to the nitrogen atom of NR6R7 at the 2-, 3- or 4-positions relative to the pyridine nitrogen.
- R in the structural formula above is a straight, saturated or unsaturated hydrocarbyl radical that contains 2 to about 16 carbon atoms.
- the R-X radical together contains three saturated carbon atoms linked together by carbon-carbon bonds.
- R is unsaturated and contains 7-16 carbon atoms.
- R is a hydrocarbon radical and therefore contains no elements other than carbon and hydrogen. Consequently, any element present in R-X that is not hydrogen or carbon is, by definition, part of the X radical.
- compositions are useful herein, and can be formed by treatment of the pyrazole with an appropriate acid.
- exemplary inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric and the like acids.
- exemplary organic acids include methanesulfonic, ethanesulfonic, benzenesulfonic and p -toluenesulfonic and the like acids.
- the acid addition salt form can be converted to the free base form by treatment with alkali.
- 1,5-Diaryl-3-substituted pyrazole compounds can include a carboxylic acid and/or a hydroxamic acid, as already noted.
- Basic salts of those carboxylic and hydroxamic acids are also contemplated, and are formed by treatment of the acid with an appropriate, non-toxic, pharmaceutically acceptable alkaline reagent to form a carboxylate or hydroxamate cation salt.
- Exemplary non-toxic, pharmaceutically acceptable cation salts of such carboxylic and hydroxamic acids include sodium, potassium, zinc, aluminum, calcium and magnesium. These salts also readily form in aqueous solutions of the carboxylic and hydroxamic acids.
- R2 and R4 are hydrogen, and R1 and R3 are selected from the group consisting of halo and lower alkoxy, especially methoxy.
- the preferred R1 and R3 substituents are preferably at the 4-positions of their respective aryl (phenyl) rings.
- R contain two carbon atoms and that X be carboxy, hydroxymethyl, a hydroxamic acid (N-hydroxy amide) or a N-lower alkyl hydroxamic acid (N-hydroxy-N-lower alkyl amide).
- 1,5-diaryl-3-substituted pyrazole compounds are named hereinbelow, followed by a parenthesized, underlined numeral for ease of identification and correlation with the syntheses and anti-inflammation study described in detail hereinafter.
- the preferred species of this invention include:
- a pharmaceutical composition that comprises an anti-inflammatory amount of a before-discussed 1,5-diaryl-3-substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier is also contemplated herein.
- the composition comprises a unit dosage of the substituted pyrazole compound.
- the substituted pyrazole compounds of this invention are capable of inhibiting the lipoxygenase enzyme pathway and/or the cyclooxygenase (prostaglandin synthetase) enzyme pathway.
- the substituted pyrazole compound of the pharmaceutical composition is capable of inhibiting both the lipoxyenase and the cyclooxygenase enzyme pathways in the amount at which that substituted pyrazole compound is present in the pharmaceutical composition, when that composition is introduced as a unit dose into an appropriate mammal such as a laboratory rat.
- unit dosage and its grammatical equivalent is used herein to refer to physically discrete units suitable as unitary dosages for human patients and other warm blooded animals, each unit containing a predetermined effective, pharmacologic amount of the active ingredient calculated to produce the desired pharmacological effect in association with the required physiologically tolerable carrier, e.g., a diluent or a vehicle.
- physiologically tolerable carrier e.g., a diluent or a vehicle.
- suitable unit dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, and the like, segregated multiples of any of the foregoing, as well as liquid solutions and suspensions.
- the active ingredient is referred to herein as being dispersed in the carrier.
- the dispersion formed can be a simple admixture, a non-settling dispersion as in the case of certain emulsions, or as an ultimate dispersion, a true solution.
- the amount of active ingredient that is administered in vivo depends on the age and weight of the mammal treated, the particular medical condition to be treated, the frequency of administration, and the route of administration.
- the dose range can be about 0.01 to about 500 milligrams per kilogram of body weight, more preferably about 0.1 to about 50 milligrams per kilogram of body weight and most preferably about 0.1 to about 25 milligrams per kilogram of body weight.
- the human adult dose is in the range of about 10 to about 2000 milligrams daily, given as a single dose or in 3 or 4 divided doses.
- Veterinary dosages correspond to human dosages with the amounts administered being in proportion to the weight of the animal as compared to adult humans.
- orally administered unit doses containing about 1 to about 50 milligrams of a 1,5-diaryl-3-substituted pyrazole per kilogram of laboratory rat body weight were useful in reducing inflammation.
- Physiologically tolerable carriers are well known in the art.
- Exemplary of liquid carriers are aqueous solutions that contain no materials in addition to the substituted pyrazole compound, or contain a buffer such as sodium phosphate at physiological pH value, saline and the like.
- Liquid compositions can also contain liquid phases in addition to and to the exclusion of water.
- additional liquid phases are glycerin and vegetable oils such as cottonseed oil.
- Exemplary solid carriers include those materials usually used in the manufacture of pills or tablets, and include corn starch, lactose, dicalcium phosphate, thickeners such as tragacanth and methylcellulose U.S.P., finely divided SiO2, polyvinylpyrrolidone, magnesium stearate and the like.
- Antioxidants such as methylparaben and propylparaben can be present in both solid and liquid compositions, as can sweeteners such a cane or beet sugar, sodium saccharin, sodium cyclamate and the dipeptide methyl ester sweeteneer sold under the trademark NUTRASWEET (aspartame) by G. D. Searle Co.
- a method for alleviating inflammation in a mammal exhibiting an inflammatory condition comprises administering to that mammal an effective amount of a pharmaceutical composition that includes a unit dose of an active ingredient that is the before-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier.
- the pharmaceutical composition is preferably maintained within the mammal until the substituted pyrazole compound is cleared from the mammal's body by natural means such as excretion or metabolism.
- the pharmaceutical composition can be administered orally, topically or by injection, by means well known in the art.
- the composition is administered orally as a tablet, capsule or aqueous dispersion.
- the method of alleviating inflammation can include administering the pharmaceutical composition a plurality of times into the treated mammal over a time period of weeks, months and years.
- the pharmaceutical composition is administered a plurality of times to the mammal over a time period of thirty days, in preferred practice.
- a method for synthesizing a 1,5-diaryl-(omega-substituted lower alkyl) pyrazole constitutes yet another aspect of the present invention.
- an aryl hydrazine or its acid addition salt is admixed in an inert polar solvent with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons, and up to about 9 carbon atoms, in the alkyl chain to form a reaction mixture.
- the aryl hydrazine and the 1,3-alkyldione are preferably reacted in substantially stoichiometric amounts.
- the omega-substituent of the 1-aryl-omega-substituted-alkyl-1,3-dione is substantially inert to the reaction conditions utilized for the cyclization reaction; i.e., the substituent does not itself react with any of the reactants or solvent during the cyclization reaction.
- exemplary of useful substituents are hydroxy and lower alkoxy as before described. Hydroxy is particulary preferred as the omega substituent.
- aryl hydrazine and aryl-alkyl-1,3-dione are reacted in an inert polar solvent medium.
- solvents are methanol, ethanol, isopropanol, pyridine, triethylamine and mixtures of those solvents.
- the reaction mixture so formed is maintained with agitation, as by stirring, for a predetermined period of time for the 1-aryl-hydrazine and the 1-aryl-(omega-substituted)-alkyl-1,3-dione to react and form the desired 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole.
- the predetermined time period is typically about 1 to about 20 hours, depending upon the reactants, solvent and reaction temperature.
- the cyclization reaction is normally carried out at ambient room temperature.
- the temperature typically rises somewhat during the cyclization, but is readily controlled. Temperatures above room temperature can also be utilized.
- the resulting substituted pyrazole can be used as is in its crude form directly after the cyclization, as where a further reaction is to be carried out with it.
- the crude reaction product formed is recovered and purified as by crystallization or column chromatography prior to use in a further reaction or to alleviate inflammation.
- reaction sequence shown thereafter in Scheme 2 relates to reactions carried out with specific compounds and in which R* is the 1-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]methylene group (as shown hereinafter); R1-R7 are as before described; lower case letters adjacent to reaction arrows indicate reaction conditions discussed thereafter below; and underlined numerals indicate specific compounds whose syntheses are described in detail hereinafter.
- a pyridinium chlorochromate
- b Jones Reagent
- c lithium hexamethyldisilazide/BrPh3P(CH2)4 CO2H
- d oxalyl chloride
- e R6NHOH
- f R6R7NH.
- the pyrazoles of formula I are oxidized to either the acid (e.g., 12 ) with, for example, Jones Reagent or to the aldehyde (e.g., 11 ) with, for example, pyridinium chlorochromate, as illustrated with compound 2 ; i.e., 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl)pyrazole.
- the olefinic acid 32 was obtained by treatment of aldehyde 11 with (4-carboxylbutyl)triphenylphosphorane.
- the appropriate acid chlorides were synthesized by treatment of acids of general formula 12 or 32 with oxalyl chloride in tetrahydrofuran (THF). The acid chlorides were then added as THF solutions to a solution of the appropriate alkylhydroxylamine hydrochloride [R6NHOH(HCl)] in THF/water/triethylamine (THF/H2O/Et3N) to afford the alkylhydroxamic acids such as compounds 3 , 58 and 41 .
- the corresponding O-acylated products e.g., 53 and 57
- that may also form in the reaction were separated by either recrystallization or chromatography.
- Example 1 5-(4-Chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole (2) .
- the reaction mixture was worked up as follows: the mixture was concentrated in vacuo and taken up in diethyl ether (250 ml); the ether solution was washed with aqueous 1N HCl (200 ml), decolorized, dried (Na2SO4), filtered through a pad of celite, and concentrated in vacuo .
- the crude material was either purified by column chromatography (silica gel 60, 70 - 230 mesh, about 250 g, and elution with ether) to give the desired 1,5-diarylpyrazoles ( I ) or recrystallized directly without chromatography. In some cases the isomeric 1,3-diaryl isomer was also isolated in varying minor amounts, and eluted before I from the column.
- R1, R2, R3 and R4 are all other than hydrogen
- aryl hydrazine B is 3,4-dimethoxyphenylhydrazine
- 1-aryl-1,3-dione A is 3,4-dichloro-4,6-dioxohexanoic acid
- 5-(3,4-dichlorophenyl)-1-(3,4-dimethoxyphenyl)-3-(3-hydroxypropyl)-pyrazole is obtained.
- Example 2 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propionic acid (12 ).
- Example 3 Sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazoyl] propanoate monohydrate (13).
- the compounds of Table 2 ⁇ -AP were synthesized by the following general procedure. To a reaction vessel containing anhydrous THF (250 ml) and diisopropylamine (14 ml, 0.1 Mole) stirring under nitrogen at 0°C was added by syringe, n-BuLi (1.6 M, 62.5 ml,0.1 Mole). The vessel was then cooled to -78°C. Alternatively, lithium hexamethyldisilazide (0.1 Mole) may be employed as the base in place of lithium diisopropylamide.
- Example 7 0-[2-[5-(4-Chlorophenyl)-1(4-methoxyphenyl)-3-pyrazolyl] ethyl-carbonyl]-N-methylhydroxylamine (53).
- Example 8 N-Carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propanamide (66).
- Example 10 3-[5-(4-Fluorophenyl)-1-(4-methoxyphenyl)- 3-pyrazolyl]-N-hydroxy-N-methyl propanamide (45).
- Example 12 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxypropanamide (29).
- Example 13 0-[2-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] ethylcarbonyl]-N- tert -butylhydroxylamine ( 57 ); and 3-[5-(4-chlorphenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-tert-butyl-N-hydroxypropanamide (58).
- reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H2O, dried (MgSO4), filtered and concentrated in vacuo . The residue was combined with that from a similar run on a 2.72 mM scale.
- Example 15 Sodium 8-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-5(Z)-octenoate (32).
- Example 16 8-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-methyl-5(Z)-octenamide (41).
- Example 17 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N,N-diethylpropanamide (28).
- Example 18 Compounds of Table 3 .
- Example 19 Compounds of Table 4 .
- Example 20 3-(3-Acetoxypropyl)-5-(4-chlorophenyl)-1-phenylpyrazole (7).
- Example 21 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propyl methyl ether (24).
- Example 22 5-(4-Chlorophenyl)-3-(3-hydroxybutyl)-1-(4-methoxyphenyl) pyrazole (20).
- Example 23 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(3-oxobutyl)pyrazole (23).
- Example 24 5-(4-Chlorophenyl)-3-(3-hydroxy-3-methylbutyl)-1-(4-methoxyphenyl) pyrazole (27).
- Example 25 5-(4-Chlorophenyl)-3-(3-oximinopropyl)-1-(4-methoxyphenyl) pyrazole (26).
- Example 26 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-[3(Z)-hexadecenyl] pyrazole (33).
- Example 27 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-[4-phenyl-3(E)-butenyl] pyrazole (14); and 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-[4-phenyl-3(E,Z)-butenyl] pyrazole (15).
- reaction mixture was diluted to 50 ml with Et2O, washed with H2O, dried (MgSO4), filtered and concentrated in vacuo Chromatography (Baker silica gel, 45 g) with Et2O:hexane (9:1) as eluent, afforded 16 (59%) as a white semi-solid.
- Example 29 3-[4-(4-Carbomethoxyphenyl)-3(E)-butenyl]-5-(4-chlorophenyl)-1-(4-methoxyphenyl) pyrazole (25).
- Example 31 3-(3-Acetoacetoxypropyl)-5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazole (59).
- Example 32 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propylamine (96).
- Example 34 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-met hyl-N-succinyloxy- propanamide.
- the compounds of Table 11 were synthesized from compounds 43 or 44 by standard methods..
- Anti-inflammatory activity of the substituted pyrazole compounds is expressed as the percent inhibition of paw volume increase.
- the results of this study for several compounds of the structure shown below are shown in Table 16, hereinafter.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
- The present invention relates to substituted pyrazole derivatives, and particularly to 1,5-diaryl 3-substituted-pyrazoles that are pharmacologically active in alleviating inflammation, asthma, hypersensitivity, myocardial ischemia, dermatological conditions such as psoriasis, dermatitis and gastrointestinal inflammatory conditions such as inflammatory bowel syndromes, and to a method for synthesizing those pyrazole derivatives.
- Nonsteroidal anti-inflammatory drugs (NSAID's) such as indomethacin, naproxen, ibuprofen, tolectin, fenoprofen and the like have generally been shown to attenuate the biosynthesis of prostaglandins by inhibiting the activity of the enzyme cyclooxygenase. The prostaglandin end-products of the cyclooxygenase pathway are responsible for many of the early signs of inflammation including hyperalgesia, increases in vascular permeability leading to edema, and pyrexia. The activity and potency of the NSAID's in reducing these signs and symptoms is, for the most part, correlated with their ability to inhibit prostaglandin biosynthesis.
- The other major pathway of arachidonic acid metabolism is the lipoxygenase pathway. Lipoxygenase products of arachidonate metabolism, the leukotrienes, hydroxyeicosatetraenoic acids (HETES) and hydroperoxyeicosatetraenoic acids (HEPTES), have been shown or implicated to be involved in disease states including acute and chronic inflammation, arthritis, allergic and other hypersensitivity disorders, dermatological diseases such as psoriasis, acne, atopic dermatitis, contact sensitivity, eczema and others, cardiovascular disorders secondary to myocardial ischemia or infarction, thromboembolism or vasculitis or platelet aggregation, and hyperalgesic disorders, gynecological disorders such as dysmenorrhea, ocular inflammation, sperm motility or function, and others.
- Leukotriene B₄ (LTB₄), another product of the lipoxygenase pathway, as well as HETES and HPETES can mediate induction of other phlogistic substances such as thromboxanes and prostacyclin, is chemotactic to inflammatory cells and is hyperalgesic. Many of these mediators have been identified in skin, lungs, coronary circulation, eyes, gastrointestinal tract and other organs, and in the synovial fluid of rheumatoid arthritic patients. In chronic inflammatory conditions such as rheumatoid arthritis, it is believed to be the chronic influx of leukocytes, probably mediated by LTB₄, that is the eventual cause of joint erosion.
- It is believed that inhibitors of the lipoxygenase pathway could lead to a relatively permanent effect on inflammatory disorders such as rheumatoid arthritis since they could modulate the actual mechanisms of tissue and joint breakdown. Similarly, drugs that could inhibit prostaglandin synthesis via the cyclooxgenase pathway could modulate and reduce early manifestations of inflammation. Pharmacologically active compounds that can inhibit both enzyme pathways at similar concentrations (dual inhibitors) provide a more complete relief for patients suffering from arthritis, hypersensitivity, dermatological, cardiovascular, gastrointestinal, ocular, and gynecological disorders than present drugs that inhibit one pathway, but not the other as is the case for usually used NSAID's that are predominantly inhibitors of the cyclooxygenase (prostaglandin synthesis) pathway.
- A number of 1,5-diaryl-3-substituted pyrazoles are reported in the literature. Some of these pyrazoles have been reported to have pharmacological activity.
- For example Fulmer et al., J. Het. Chem., 17:799-800 (1980) report the synthesis of 1,3,5-triaryl pyrazoles, as do Foote et al., J. Het. Chem., 7:89-92 (1970), Beam et al., J. Het. Chem., 9:183-185 (1972); Soliman et al., J. Pharm. Sci., 70:606-610 (1981), and Barluenga et al., J.C.S. Chem. Comm., 891 (1979). Soliman et al., J. Pharm. Sci., 70:602-605 (1981) also report synthesis of 3-methyl-1,5-diarylpyrazoles in which the 1-position aryl is a phenylsulfonylurea or thiourea. Of the above reports, only the two reports by Soliman et al. discuss any pharmacological activity for the pyrazoles prepared or for analogs of those pyrazoles, and those materials are reported to have hypoglycemic activity.
- Virmani et al., Indian J. Chem., Sect. B, 17B: 472-477 (1979) report the synthesis of 3-omega-alkylaminoalkyl pyrazoles among other compounds. The 1,5-diaryl-3-substituted pyrazoles reported contained a phenyl group at the 1-position, a 4-nitrophenyl at the 5-position, and a (CH₂)n-NHCH₃ group at the 3-position, where n is 3,4 or 5 (3-5). This report stated that the compounds prepared were screened for a number of biological activities, with nine of the ninety-four numbered compounds synthesized having mild anti-inflammatory activity, two others having diuretic activity and two others having weak anti-cancer activity. The above-discussed 1,5-diaryl-3-substituted pyrazoles were not among the compounds reported to have any pharmacological activity.
- Vereshchagin et al., Zh. Org. Khim., 7:907-912 (1971) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles. The 3-substituents were reported to be alkoxy alkylene in which the alkoxy radical was methoxy or phenoxy and the alkylene was methylene or isopropylene, while the 1,5-diaryl radicals were unsubstituted phenyl.
- Jahn and Wagner-Jauregg, Arzneim-Forsch. (Drug Res.), 24:494-499 (1974) reported the synthesis and some pharmacological activities of
1,5-diaryl-3-substituted-4,5-dihydropyrazoles. The aryl group at the 1-position for each reported compound was phenyl, while the 5-aryl substituent was reported to be phenyl, 4-methoxyphenyl, 3-methoxy-4-hydroxyphenyl, and 2-hydroxyphenyl. The before-mentioned pyrazoles were substituted at the 3-position by bonding to the 3-position of propionic acid or propiohydroxamic acid. These compounds were said to possess antirheumatic activity. - Shawali et al., J. Het. Chem., 13:989-92 (1976); Shawali, J. Het. Chem., 14:375-81 (1977); and Matsumoto et al., Bull. Chem. Soc. Japan, 47: 946-949 (1979) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles, all of which also included a substituent other than hydrogen at the 4-position on the pyrazole ring. Exemplary 4-position substituents were reported to include cyano, amino, carboethyoxy, and phenylcarbonyl. These reports included no mention of biological activity of the compounds reported.
- A series of benzimidoylpyrazoles was reported by Shrof et al., J. Med. Chem., 24:1521-1525 (1981). These compounds were reported to possess activities of sulfonyl urea and biguanide hypoglcemics.
- Biere et al., Arch. Phar., 316:608-616 (1983) reported the synthesis of 1,4-diaryl-pyrazole-3-acetic acid derivatives, some of which also contained a an aryl substituent at the 5-position. The synthesized compounds were assayed for use as anti-inflammatory drugs in rats. The compounds assayed that also contained 5-position substituents were reported to be relatively inactive.
- A further group of 1,5-diphenyl-4-substituted-pyrazole-3-acetic acids was reported by El-Sayed and Ohta, Bull. Chem. Soc. Japan, 46:1801-1803 (1973). Those compounds were utilized as intermediates in the synthesis of pyrazolo-[4,3-c]-pyridines. Another group of 1,5-diphenyl-4-substituted-pyrazoles, some of which also include methyl, phenyl and carboxymethyl groups at the 3-position, was reported in Al-Saleh et al., J.C.S. Perkin I, 642-645 (1981). The reports of El-Sayed and Ohta and those of Al-Saleh et al. make no mention of the pharmacological properties of the pyrazole derivatives reported. Another group of 1,5-diaryl-3,4-disubstituted pyrazoles and 4,5-dihydro-5-hydroxy pyrazoles was reported in Fusco and Croce, Gazz. Chim. Ital., 101:703-272 (1971).
- The present invention contemplates 1,5-diaryl-3-substituted pyrazoles, their use and a method of their synthesis. The compounds of the present invention are pharamacologically active in alleviating inflammation, and inhibit the cyclooxygenase enzyme pathway, the lipoxygenase enzyme pathway, or preferably both pathways.
- In particular, the invention contemplates a substituted pyrazole compound having a structure that conforms to the formula
R₁, R₂, R₃ and R₄ are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, amino, acetamido, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, ω-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R₁, R₂ or R₃, R₄ taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group;
R is a straight, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;
Y is hydrogen, bromo, chloro or lower alkyl having 1-4 carbon atoms;
and X is selected from the group consisting of carboxy, carboloweralkoxy, hydroxy, acetoxy, alkanoyloxy, lower alkoxy, lower alkyl carbonyl, oximo, cyano, amino, C(O)-R₅ and -C(O)C(O)-R₅ wherein R₅ is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR₆R₇ wherein R₆ and R₇ are the same or different and are selected from the group consisting of hydrogen, and lower alkyl, or R₆ or R₇ are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, hydroxy, lower acyloxy, benzyloxy, 2-hydroxy lower alkyl, lower alkyl carboxy, phenyl, substituted phenyl, pyridyl, thiazolyl, dihydrothiazolyl, ω-alkanoate, 5-tetrazolyl, -OCO(CH₂)nCOR₉ wherein R₉ is -OH, -ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; -OCOR₁₀ wherein R₁₀ is -CH₂NR₁₁R₁₂ wherein R₁₁ and R₁₂ are alkyl, such as methyl, cycloalkyl such as cyclohexyl, or together are a heterocyclic ring such as N-methylpiperazino, -OCOR₁₀ wherein R₁₀ is -CH₂Cl, -CH₂O-loweralkyl or t-butyl, -CH-loweralkyl-CO₂-Q, wherein Q is lower alkyl or -H, acyl such as acetyl, propionyl or butyryl; -NR₈OH wherein R₈ is hydrogen, -CO-loweralkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, SO₂-lower alkyl, -COCO₂-lower alkyl, and -COCONHOH; -NHR₁₃ wherein R₁₃ is hydrogen, -CO-lower alkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, -SO₂-lower alkyl, -COCO₂-lower alkyl, -COCONHOH, -COCO₂H, COCON(lower alkyl)OH, and PO(O-lower alkyl)₂; -C(R₁₄)=NNH-2-thiazolino, -CH(OH)R₁₄ and -C(O)R₁₄ wherein R₁₄ is hydrogen, lower alkyl, phenyl and t-butyl; -C(=NOH)NH₂ and -C(=NH)N(OH)-lower alkyl and O-NR₈R₉ wherein R₈ and R₉ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl;
with the provisos that: - (a) when Y is bromo or chloro, X is -COOH, -CH₂OH or -C(O)-R₅ wheren R₅ is NR₆R₇ and R₆ is -OH and R₇ is lower alkyl;
- (b) at least one of R₁ and R₂ is other than hydrogen where (i) R-X is (CH₂)₂CO₂H or (CH₂)₂C(O)NHOH and (ii) R₃ and R₄ are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen; and
- (c) at least one of R₁ and R₂, or one of R₃ and R₄ is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts thereof.
- In preferred practice, R₂ and R₄ are hydrogen, and R₁ and R₃ are selected from the group consisting of halo, trifluroromethyl, lower alkyl and lower alkoxy, especially methoxy. R preferably contains two carbon atoms. It is also preferred that the X be hydroxyloweralkyl, carboxy, a hydroxamic acid or a N alkyl hydroxamic acid; i.e., that X be C(O)NR₆R₇ where R₆ is hydroxy and R₇ is hydrogen or lower alkyl or a N-alkyl hydroxamic acid; i.e. that x is -C(O)NR₆R₇ wheren R₆ is hydroxy or -OC(O)CH₂Z where Z is dialkylamino or -CH₂CO₂H and R₇ is hydrogen or lower alkyl.
- The present invention also contemplates a pharmaceutical composition that comprises an anti-inflammatory amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier. The dose may be administered by topical, p.o., parenteral or aerosol routes. In preferred practice, that substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and the lipoxygenase pathways in the amount present in the composition, when the composition is introduced into a mammal.
- Further contemplated is a method for alleviating inflammation in a mammal exhibiting an inflammatory condition. That method comprises administering to that mammal a pharmaceutical composition that includes as the active ingredient an effective amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier for topical, oral, parenteral and aerosol administration.
- A method for synthesizing a
1,5-diaryl-3-(omega-substituted lower alkyl)pyrazole is also contemplated. In accordance with this method, an aryl hydrazine or its acid addition salt is reacted with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain. A polar solvent is used that is substantially inert to the reaction conditions, as is the omega-substituent of the alkyl 1,3-dione. The resulting 1,5-diaryl-3-(omega lower alkyl substituted) pyrazole is thereafter preferably recovered, although it can be utilized in the form of its synthesis (crude form), as for further syntheses. Particularly preferred alkyl-1,3-dione derivatives contain 6 carbons in the alkyl chain and contain a hydroxy group as the omega-substituent. - The present invention provides several benefits and advantages.
- A particular benefit of the invention is that it provides pharmacologically active compounds that are useful in treating inflammatory conditions.
- A particular advantage of the present invention is that its synthetic method provides relatively high yields of 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole compounds.
- Another benefit of the present invention is that some of its pharmacologically active compounds inhibit the cyclooxygenase enzyme pathway, thereby providing a further means for studying that biological process.
- Another advantage of the present invention is that some of its pharmacologically active compounds inhibit the lipoxygenase enzyme pathway, thereby providing a further means for studying that biological process.
- Still further benefits and advantages of the present invention will be apparent to those skilled in the art from the detailed description and Examples that follow.
- 1,5-Diaryl-3-substituted pyrazole compounds, pharmaceutical compositions containing a substituted pyrazole compound as an active ingredient, a method of treating a mammal exhibiting an inflammatory condition and a method of synthesizing the substituted pyrazole compound are contemplated herein.
- In the above formula, R₁, R₂, R₃ and R₄ are substituents on phenyl rings that substitute for hydrogen atoms at positions 1 and 5 of the pyrazole ring. It is preferred that at least one of R₁ and R₂, and one of R₃ and R₄ be substituted at the 4-positions of their respective phenyl rings.
- In examining the above structural formula to which the useful pyrazole compounds conform, it is noted that the R₁, R₂, R₃ and R₄ radicals and the X group can be a "lower" alkyl, "lower" alkoxy and the like. Groups and radicals referred to as "lower" denote that they possess 1 to about 6 carbon atoms. The same is true for "lower" groups and radicals that are sustituents of the "lower" groups and radicals enumerated.
- To the extent that X substituents are defined as being the same as those of R₁, R₂ R₃ and R₄, those commonly defined substituents are discussed immediately below. Additional X substituents that are not common to X and R₁, R₂, R₃ and R₄ are discussed thereafter.
- Lower alkyl radicals include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n-hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, octyl and the like.
- Lower alkoxy radicals are oxygen ethers formed from a before-described lower alkyl group. Exemplary radicals include methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, and the like.
- Lower alkylthio radicals of R₁,R₂,R₃ and R₄ are sulfide ethers and are thus analogous to the oxygen ethers described above.
- Halo radicals preferably include chloro and bromo, as well as fluoro and iodo.
- Lower alkylsulfonyl radicals contain a before-described lower alkyl radical bonded to an SO₂ moiety that is itself also bonded to a phenyl ring. Exemplary lower alkylsulfonyl radicals thus include methylsulfonyl, ethylsulfonyl, 2-ethylbutylsulfonyl and the like.
- An omega-trifluoromethyl lower alkoxy radical is a lower alkoxy radical as before described that additionally includes a trifluoromethyl group at a position farthest on the alkyl chain from the place of bonding to the phenyl ring. Exemplary of such radicals are the 2,2,2-trifluoroethoxy.
- Naphthyl and substituted naphthyl radicals can replace an aryl group herein at either the 1- or 2-positions to provide 1-naphthyl or 2-napththyl substituents, respectfully. Substituents on the naphthyl radicals can be any of those described herein as being useful aryl substituents. Exemplary substituted 1- and 2-naphthyls include 6-methoxy-2-naphthyl and the like.
- Lower alkyl carboxy radicals are the before-described lower alkyl radicals that further include a carboxy group. Exemplary lower alkyl carboxy radicals include carboxymethyl, 2-carboxyhexyl and the like. Lower alkyl lower alkoxy carbonyl radicals are lower alkyl esters of lower alkyl carboxy radicals. Exemplary lower alkyl lower alkoxy carbonyl radicals include 3-isopropoxycarbonylpropyl, 4-hexyloxycarbonylpentyl and the like.
- A lower alkyl carbonyl radical contains a carbonyl group, a total of up to six carbon atoms, and with the portion of R to which it is linked, forms a ketone at the R/X junction. Exemplary lower alkyl carbonyl radicals include acetyl, propionyl 2-methylpropionyl, pentoyl and the like, which can also be named methyl carbonyl, ethyl carbonyl, isopropylcarbonyl and butylcarbonyl, respectively.
- Radicals in which X is C(O)-R₅ where in R₅ is lower alkoxy are carboxylic esters. These esters are preferably named by considering R-X to be a single substituent entity. Exemplary R₅ lower alkoxy groups are as before described, although methoxy and ethoxy are preferred. When R₅ is NR₆R₇ and ONR₈R₉, it is also useful to consider R-X as a substituent entity.
- Lower hydroxy alkyl radicals of R₆ and R₇ are preferably 2-hydroxyethyl and 2-hydroxypropyl. Additionally useful lower hydroxy alkyl radicals include 4-hydroxybutyl and the like.
- Substituted phenyl radicals that can comprise NR₆R₇ are the same as the substituted aryl groups described before wherein R₁, R₂, R₃ and R₄ comprise the substituents.
- Pyridyl radicals are derivatives of pyridine and can be bonded to the nitrogen atom of NR₆R₇ at the 2-, 3- or 4-positions relative to the pyridine nitrogen.
- R in the structural formula above is a straight, saturated or unsaturated hydrocarbyl radical that contains 2 to about 16 carbon atoms. In particularly preferred practice, the R-X radical together contains three saturated carbon atoms linked together by carbon-carbon bonds. In other preferred embodiments, R is unsaturated and contains 7-16 carbon atoms.
- R is a hydrocarbon radical and therefore contains no elements other than carbon and hydrogen. Consequently, any element present in R-X that is not hydrogen or carbon is, by definition, part of the X radical.
- Pharmaceutically acceptable, non-toxic acid addition salts of 1,5-diaryl-3-substituted-pyrazole compounds are useful herein, and can be formed by treatment of the pyrazole with an appropriate acid. Exemplary inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric and the like acids. Exemplary organic acids include methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic and the like acids. Conversely, the acid addition salt form can be converted to the free base form by treatment with alkali.
- 1,5-Diaryl-3-substituted pyrazole compounds can include a carboxylic acid and/or a hydroxamic acid, as already noted. Basic salts of those carboxylic and hydroxamic acids are also contemplated, and are formed by treatment of the acid with an appropriate, non-toxic, pharmaceutically acceptable alkaline reagent to form a carboxylate or hydroxamate cation salt. Exemplary non-toxic, pharmaceutically acceptable cation salts of such carboxylic and hydroxamic acids include sodium, potassium, zinc, aluminum, calcium and magnesium. These salts also readily form in aqueous solutions of the carboxylic and hydroxamic acids.
- In preferred practice, R₂ and R₄ are hydrogen, and R₁ and R₃ are selected from the group consisting of halo and lower alkoxy, especially methoxy. The preferred R₁ and R₃ substituents are preferably at the 4-positions of their respective aryl (phenyl) rings.
- It is prefered that R contain two carbon atoms and that X be carboxy, hydroxymethyl, a hydroxamic acid (N-hydroxy amide) or a N-lower alkyl hydroxamic acid (N-hydroxy-N-lower alkyl amide).
- Specific, particularly preferred 1,5-diaryl-3-substituted pyrazole compounds are named hereinbelow, followed by a parenthesized, underlined numeral for ease of identification and correlation with the syntheses and anti-inflammation study described in detail hereinafter.
- The preferred species of this invention include:
- 1. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-methylpropanamide, (3)
- 2. 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole, (2)
- 3. 5-(4-trifluoromethylphenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole, (56)
- 4. 1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(3-hydroxypropyl) pyrazole, (35)
- 5. sodium 8-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-5(Z)-octenoate, (32)
- 6. sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propanoate, (13)
- 7. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-tert-butyl-N-hydroxypropanamide, (57)
- 8. N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propanamide, (66)
- 9. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-isopropylpropanamide (81)
- 10. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-cyclohexyl-N-hydroxypropanamide (82)
- 11. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-ethyl-N-hydroxypropanamide (83)
- 12. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-phenylpropanamide (84)
- 13. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propylamine (96)
- 14. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]propanal (11)
- 15. 5-(4-chlorophenyl)-3-(3-oximinopropyl)-1-(4-methoxyphenyl)pyrazole (26)
- 16. 3-(3-hydroxypropyl)-1-(4-methoxyphenyl)-5-(4-tolyl)pyrazole (55)
- A pharmaceutical composition that comprises an anti-inflammatory amount of a before-discussed 1,5-diaryl-3-substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier is also contemplated herein. The composition comprises a unit dosage of the substituted pyrazole compound.
- The substituted pyrazole compounds of this invention are capable of inhibiting the lipoxygenase enzyme pathway and/or the cyclooxygenase (prostaglandin synthetase) enzyme pathway. In preferred practice, the substituted pyrazole compound of the pharmaceutical composition is capable of inhibiting both the lipoxyenase and the cyclooxygenase enzyme pathways in the amount at which that substituted pyrazole compound is present in the pharmaceutical composition, when that composition is introduced as a unit dose into an appropriate mammal such as a laboratory rat.
- The term "unit dosage" and its grammatical equivalent is used herein to refer to physically discrete units suitable as unitary dosages for human patients and other warm blooded animals, each unit containing a predetermined effective, pharmacologic amount of the active ingredient calculated to produce the desired pharmacological effect in association with the required physiologically tolerable carrier, e.g., a diluent or a vehicle. The specifications for the novel unit dosage forms of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active ingredient, and (b) the limitations inherent in the art of compounding such an active ingredient for therapeutic use in humans and other animals. Examples of suitable unit dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, and the like, segregated multiples of any of the foregoing, as well as liquid solutions and suspensions.
- The active ingredient is referred to herein as being dispersed in the carrier. Thus, the dispersion formed can be a simple admixture, a non-settling dispersion as in the case of certain emulsions, or as an ultimate dispersion, a true solution.
- The amount of active ingredient that is administered in vivo depends on the age and weight of the mammal treated, the particular medical condition to be treated, the frequency of administration, and the route of administration. The dose range can be about 0.01 to about 500 milligrams per kilogram of body weight, more preferably about 0.1 to about 50 milligrams per kilogram of body weight and most preferably about 0.1 to about 25 milligrams per kilogram of body weight. The human adult dose is in the range of about 10 to about 2000 milligrams daily, given as a single dose or in 3 or 4 divided doses. Veterinary dosages correspond to human dosages with the amounts administered being in proportion to the weight of the animal as compared to adult humans.
- As is seen from the data discussed hereinafter, orally administered unit doses containing about 1 to about 50 milligrams of a 1,5-diaryl-3-substituted pyrazole per kilogram of laboratory rat body weight (e.g., about 200 grams each) were useful in reducing inflammation. These results are contrary to those reported by Virmani et al., Indian J. Chem., Sect. B, 17:472-477 (1979) who reported compounds that are structurally similar to those described herein were not active as anti-inflammatory agents.
- Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are aqueous solutions that contain no materials in addition to the substituted pyrazole compound, or contain a buffer such as sodium phosphate at physiological pH value, saline and the like.
- Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin and vegetable oils such as cottonseed oil.
- Exemplary solid carriers (diluents) include those materials usually used in the manufacture of pills or tablets, and include corn starch, lactose, dicalcium phosphate, thickeners such as tragacanth and methylcellulose U.S.P., finely divided SiO₂, polyvinylpyrrolidone, magnesium stearate and the like. Antioxidants such as methylparaben and propylparaben can be present in both solid and liquid compositions, as can sweeteners such a cane or beet sugar, sodium saccharin, sodium cyclamate and the dipeptide methyl ester sweeteneer sold under the trademark NUTRASWEET (aspartame) by G. D. Searle Co.
- A method for alleviating inflammation in a mammal exhibiting an inflammatory condition is also contemplated. The method comprises administering to that mammal an effective amount of a pharmaceutical composition that includes a unit dose of an active ingredient that is the before-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier. The pharmaceutical composition is preferably maintained within the mammal until the substituted pyrazole compound is cleared from the mammal's body by natural means such as excretion or metabolism.
- The pharmaceutical composition can be administered orally, topically or by injection, by means well known in the art. In preferred practice, the composition is administered orally as a tablet, capsule or aqueous dispersion.
- Inasmuch as a pharmaceutial composition can be administered 3 to 4 times daily (per 24 hour period), the method of alleviating inflammation can include administering the pharmaceutical composition a plurality of times into the treated mammal over a time period of weeks, months and years. The pharmaceutical composition is administered a plurality of times to the mammal over a time period of thirty days, in preferred practice.
- A method for synthesizing a 1,5-diaryl-(omega-substituted lower alkyl) pyrazole constitutes yet another aspect of the present invention. Here, an aryl hydrazine or its acid addition salt is admixed in an inert polar solvent with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons, and up to about 9 carbon atoms, in the alkyl chain to form a reaction mixture. The aryl hydrazine and the 1,3-alkyldione are preferably reacted in substantially stoichiometric amounts.
- The omega-substituent of the 1-aryl-omega-substituted-alkyl-1,3-dione is substantially inert to the reaction conditions utilized for the cyclization reaction; i.e., the substituent does not itself react with any of the reactants or solvent during the cyclization reaction. Exemplary of useful substituents are hydroxy and lower alkoxy as before described. Hydroxy is particulary preferred as the omega substituent.
- The aryl hydrazine and aryl-alkyl-1,3-dione are reacted in an inert polar solvent medium. Exemplary of such solvents are methanol, ethanol, isopropanol, pyridine, triethylamine and mixtures of those solvents.
- The reaction mixture so formed is maintained with agitation, as by stirring, for a predetermined period of time for the 1-aryl-hydrazine and the 1-aryl-(omega-substituted)-alkyl-1,3-dione to react and form the desired 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole. The predetermined time period is typically about 1 to about 20 hours, depending upon the reactants, solvent and reaction temperature.
- The cyclization reaction is normally carried out at ambient room temperature. The temperature typically rises somewhat during the cyclization, but is readily controlled. Temperatures above room temperature can also be utilized.
- The resulting substituted pyrazole can be used as is in its crude form directly after the cyclization, as where a further reaction is to be carried out with it. Preferably however, the crude reaction product formed is recovered and purified as by crystallization or column chromatography prior to use in a further reaction or to alleviate inflammation.
- Further reactions can be carried out on the omega-substituent of the pyrazole-3-lower alkyl group inasmuch as that substituent is substantially inert to the reaction conditions for cyclization and formation of the pyrazole ring, but need not be inert to all reaction conditions.
- An exemplary, generalized reaction sequence is shown below in Scheme 1 where a 1-(R₃,R₄-disubstituted phenyl)-6-hydroxy-hexan-1,3-dione and R₁,R₂-disubstituted phenyl hydrazine hydrochloride are reactants (A) and (B), respectively, that react to form 1-(R₁,R₂-disubstituted phenyl)-5-(R₃,R₄-disubstituted phenyl)-3-(3-hydroxypropyl)-pyrazole, I, wherein R₁,R₂,R₃ and R₄ are as previously defined. The parenthesized numerals beneath the structual formula of I refer to compounds of that structure that are exemplified hereinafter.
- The reaction sequence shown thereafter in Scheme 2 relates to reactions carried out with specific compounds and in which R* is the 1-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]methylene group (as shown hereinafter); R₁-R₇ are as before described; lower case letters adjacent to reaction arrows indicate reaction conditions discussed thereafter below; and underlined numerals indicate specific compounds whose syntheses are described in detail hereinafter.
- Treatment of the appropriate aryl diketone A wherein R₃ and R₄ are defined as before with arylhydrazine B wherein R₁ and R₂ are defined as before gives the 1,5-diarylpyrazoles I that are isolated by recrystallization or chromatography on silica from the corresponding 1,3-diarylpyrazoles formed as minor products of the reaction.
- The pyrazoles of formula I are oxidized to either the acid (e.g., 12) with, for example, Jones Reagent or to the aldehyde (e.g., 11) with, for example, pyridinium chlorochromate, as illustrated with compound 2; i.e., 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl)pyrazole. The olefinic acid 32 was obtained by treatment of aldehyde 11 with (4-carboxylbutyl)triphenylphosphorane.
- The appropriate acid chlorides were synthesized by treatment of acids of general formula 12 or 32 with oxalyl chloride in tetrahydrofuran (THF). The acid chlorides were then added as THF solutions to a solution of the appropriate alkylhydroxylamine hydrochloride [R₆NHOH(HCl)] in THF/water/triethylamine (THF/H₂O/Et₃N) to afford the alkylhydroxamic acids such as compounds 3, 58 and 41. The corresponding O-acylated products (e.g., 53 and 57) that may also form in the reaction were separated by either recrystallization or chromatography.
- Similarly, treatment of the acid chlorides above with amines of general formula R₆R₇NH gave amides such as 28, 65 and 38, where R₆ and R₇ are as before defined.
- Oxidation of compound 65 with Jones Reagent as above gave acid 66.
- The remaining compounds of this invention were synthesized by standard methods from pyrazole alcohol 2, aldehyde 11 or acid 12 as shown in Scheme 3, below. The substituted pyrazole compounds with unsaturated side chains at the 3-position were prepared by reaction of aldehyde 11 with the appropriate Wittig reagent, as discussed specifically hereinafter and shown in Scheme 2, above. R₁-R₇, lower case letters and underlined numerals are as described for Schemes 1 and 2, before. R* in Scheme 3 is the 1-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl-ethylene group, as shown.
(4-methoxycarbonylphenyl)-triphenylphosphonium chloride [4-CO₂MePhCH₂P⁺Ph₃Cl⁻].
- Melting point (mp) were determined on a Thomas-Hoover apparatus, and are uncorrected. The infrared (IR) spectra were recorded on a Beckman Instruments IR-8 spectrophotometer and are expressed in reciprocal centimeters. Nuclear magnetic resonance (NMR) spectra for hydrogen atoms were measured in the indicated solvent with tetramethylsilane (TMS) as the internal standard on a Varian T-60A or an IBM WP-100 spectrometer. The values are expressed in parts per million downfield from TMS. Parenthesized, underlined hydrogens were assigned to the resonance positions immediately before the parentheses. EI and CI mass spectra were obtained on a Finnigan 1015D quadrupole mass spectrometer coupled to a Finnigan 9500 gas chromatograph or a Finnigan MAT 8230 Double Focusing high resolution mass spectrometer.
- 4-Methoxyphenylhydrazine hydrochloride [35.0 grams (g), 0.20 moles] was added to CH₃OH [50 milliters (ml)] containing pyridine (20 ml). An additional amount of CH₃OH (25 ml) was added to the thick resulting slurry. 1-(4-Chlorophenyl)-6-
hydroxyhexan-1,3-dione (48.2g, 0.20 moles), was added neat, followed by more CH₃OH (25 ml). The slurry was stirred at room-temperature for 1.5 hours, after which times the mixture was concentrated and taken up in CHCl₃ (300 ml). The CHCl₃ solution was washed with 1N HCl (300 ml), dried (Na₂SO₄), filtered, and concentrated. The oil was decolorized (Norit) in hot diethyl ether (Et₂O) (300 ml). The Et₂O solution was cooled, and crystallization from Et₂O (300 ml) afforded 2 (49.4 g). From the filtrate was obtained additional 2 (9.28 g), total yield 91%, mp 87.5 - 88°. NMR (CDCl₃) 1.7 - 2.3 (m, 2H, CH₂CH₂CH₂), 2.55 (brs, 1H, OH), 2.80 (t, 2H, J=7Hz, CH₂), 3.75 (t, 2H, J=6Hz, CH₂O), 3.77 (s, 3H, OCH₃), 6.28 (s, 1H, C₄-H), 6.93 (ABq, 4H, J=12, 9, 4-OMe-C₆H₄), 6.9 - 7.3 (m, 4H, 4-Cl-C₆H₄); IR (KBr) 3320, 2920, 1495; MS, m/e 342 (M+), 312, 298 (100%);
Anal. Calcd. for C₁₉H₁₉ClN₂O₂:C,66.56,H,5.59;N,8.17
Found:C,66.54;H,5.76;N,8.02 - The following general procedure was used for the preparation of 1,5-diaryl-3-(3-hydroxypropyl) pyrazoles of Tables 1 and 2 that follow.
- The appropriate aryl hydrazine or hydrazine hydrochloride B [10 millimoles (Mm)] was dissolved in a solution of methanol (25 ml) containing pyridine (1 ml). The appropriately substituted 1-aryl-1,3-dione A (10 Mm) was admixed in a single portion. In a short time, the mixture warmed slightly, darkened, and became homogeneous. After stirring at ambient temperature for a time period of from 2 to 20 hours, the reaction mixture was worked up as follows: the mixture was concentrated in vacuo and taken up in diethyl ether (250 ml); the ether solution was washed with aqueous 1N HCl (200 ml), decolorized, dried (Na₂SO₄), filtered through a pad of celite, and concentrated in vacuo. The crude material was either purified by column chromatography (silica gel 60, 70 - 230 mesh, about 250 g, and elution with ether) to give the desired 1,5-diarylpyrazoles (I) or recrystallized directly without chromatography. In some cases the isomeric 1,3-diaryl isomer was also isolated in varying minor amounts, and eluted before I from the column.
- Compounds in which R₁, R₂, R₃ and R₄ are all other than hydrogen can be synthesized by the above procedure. For example, when the aryl hydrazine B is 3,4-dimethoxyphenylhydrazine and the 1-aryl-1,3-dione A is 3,4-dichloro-4,6-dioxohexanoic acid, 5-(3,4-dichlorophenyl)-1-(3,4-dimethoxyphenyl)-3-(3-hydroxypropyl)-pyrazole is obtained.
- To a solution of the alcohol 2 [(0.92 g, 2.68 millimoles (mM)] in acetone (25 ml) was added a 2N H₂Cr₂O₇ (Jones Reagent) solution (3.02 ml, 6.04 mM) dropwise over a 10 minute time period. After stirring for 1 hour the reaction solution was decanted from the chromium precipitates on the sides of the reaction vessel. The reaction solution was concentrated in vacuo and taken up into ethyl acetate (EtOAc) (100 ml), washed with distilled H₂O until the washes were clear, dried (MgSO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O: hexane afforded 12 (0.88 g, 92%) as an off-white crystalline solid, mp = 126 - 128°C.
NMR: (CDCl₃) 2.7 - 3.2 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic), 7.5 - 8.5 (1H, -COOH); IR (KBr) 1700; MS, m/e 356 (M⁺), 312, 311 (100%).
Anal. Calcd. for C₁₉H₁₇ClN₂O₃: C,63.95;H,4.80;N,7.85
Found: C,63.82;H,4.92;N,7.72. - To the acid 12 (1.0169 g, 2.85 mM) was added a 1.00 N NaOH solution (2.85 ml, 2.85 mM) and distilled H₂O (15 ml). The reaction mixture was stirred until it was homogeneous, and then lyophilized to afford 13 (1.08 g, 98%) as a white solid, with a mp greater than 300°C.
NMR (CD₃OD) 2.3 - 3.2 (m, 4H, -CH₂-CH₂-), 3.80 (s, 3H, -OCH₃) , 6.47 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 3250, 1640.
Anal. Calcd. for C₁₉H₁₆ClN₂NaO₃.H₂O:C,57.51;H,4.57;N,7.06
Found: C,57.19;H,4.33;N,6.98. - Following the procedure for compound 12 but substituting compound 1 for 2 afforded 17 (0.86 g, 68%) as a white crystalline solid, mp = 138 - 139°C.
NMR (CDCl₅) 2.6 - 3.2 (m, 4H, -CH₂-CH₂-), 6.30 (s, 1H, C₄-H); 6.4 - 7.5 (m, 10H, aromatic and -COOH). IR (KBr) 3460, 1740; Ms, m/e 326 (M⁺), 282, 281 (100%).
Anal. Calcd. for C₁₀H₁₅ClN₂O₂:C,66.16:H,4.63;N,8.57
Found;C,66.48;H,4.72;N,8.59. - To a solution of the acid 12 (0.99 g, 2.77 mM) in tetrahydrofuran (THF) (20 ml) at 0°C, was added one drop of dimethyl formamide (DMF) and oxalyl chloride (0.29 ml, 33 mM). After 0.5 hours the cooling bath was removed and stirring was continued for an additional 0.5 hours. The reaction mixture was concentrated in vacuo to remove any excess oxalyl chloride, and the acid chloride of 12, was taken up into THF (10 ml).
- To a solution of methylhydroxylamine hydrochloride (0.35 g, 4.16 mM) and triethylamine (Et₃N) (1.55 ml, 11.10 mM) in THF, H₂O (10 ml:5 ml) at 0°C, was added the THF solution of the acid chloride dropwise over a 5 minutes period. The cooling bath was removed, and the reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H₂O, dried (MgSO₄), filtered, and concentrated in vacuo. Chromatography (Baker silica gel, 45g) of the residue with EtOAc as eluent, followed by crystallization from Et₂O afforded pure 3 (0.70 g, 65%), mp = 113 - 115°C. Further recrystallization from ethyl acetate afforded white crystalline solid, m.p. 125-26°C.
NMR: (CDCl₃) 2.7 - 3.5 (m, 4H, -CH₂CH₂-), 3.18 (broad s, 3H, -N-CH₃), 3.83 (s, 3H,-OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic), 10.67 (broad s, 1H, -N-OH); IR (KBr) 3160, 1640; MS, m/e 385 (M⁺), 339 (100%).
Anal. Calcd. for C₂₀H₂₀ClN₃O₃:C,62.25:H,5.22:N,10.89
Found:C,62.60;H,5.18;N,10.82. - The following general procedure was used for the preparation of the
1,5-diaryl-3-pyrazole propionic acids of Table 2ʺ. - A mixture of the appropriate
6-aryl-4,6-diketohexanoic acid (0.1 Mole) from Table 2ʺ -AP in methanol (750 ml) containing Et₃N (0.2 Mole) was treated with 4-methoxyphenylhydrazine hydrochloride (17.4 g, 0.1 Mole) at room temperature for 1 hour. If the reaction was incomplete at this point, it was refluxed until complete. The resulting darkened solution was evaporated in vacuo and taken up in Et₂O (700 ml); the ether solution was washed with aqueous 1N HCl (350 ml), brine, dried (Na₂SO₄), decolorized, evaporated in vacuo and recrystallized from Et₂O. - The compounds of Table 2ʺ were synthesized directly from the appropriate 4,6-diketohexanoic acid as described below.
- The compounds of Table 2ʺ -AP were synthesized by the following general procedure. To a reaction vessel containing anhydrous THF (250 ml) and diisopropylamine (14 ml, 0.1 Mole) stirring under nitrogen at 0°C was added by syringe, n-BuLi (1.6 M, 62.5 ml,0.1 Mole). The vessel was then cooled to -78°C. Alternatively, lithium hexamethyldisilazide (0.1 Mole) may be employed as the base in place of lithium diisopropylamide.
- The appropriately substituted acetophenone (0.1 Mole) in anhydrous THF (50ml) was added and the resulting solution allowed to stir for 30 minutes at -78° and succinic anhydride (4.0 g, 0.04 mole) in THF (100 ml) was added via syringe. The solution was allowed to stir for 1 hour at -78°, warmed to room temperature for 1 hour and poured into 5% HCl (250 ml). The mixture was extracted with Et₂O (2 × 300ml) and the combined ether extract was extracted with 10% NaOH (100 ml). The NaOH layer was separated and acidified with 4N HCl, and reextracted with Et₂O (2 × 300 ml). The combined ether layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The resultant residues were recrystallized from the appropriate solvent to give the compounds of Table 2ʺ -AP.
- To hydroxamic acid 3 (0.6052 g, 1.57 mM) was added 1.00 N NaOH solution (1.57 ml, 1.57 mM) and distilled H₂O (3 ml). The reaction mixture was stirred for 10 minutes at which time it was homogeneous. Lyophilization afforded pure 3a (0.64 g, 97%) as a white hygroscopic solid, mp = 100 - 110°C (decomposed).
NMR: (CD₃OD) 2.3 - 3.4 (m, 4H, -CH₂CH₂-), 2.92 (broad s, 3H, -NCH₃), 3.78 (s, 3H, -OCH₃), 6.47 (s, 1H, C₄-H), 6.7 - 7.6 (m, 8H, aromatic); IR (KBr) 3420, 1600; MS, m/e 384 (M-Na).
Anal. Calcd. for C₂₀H₁₉ClN₃NaO₃.H₂O:C,56.40;H,4.97;N,9.87
Found;C,56.24;H,4.53;N,9.70. - The procedure to synthesize compound 3 was repeated on a twenty-fold scale.
- Chromatography of the crude reaction mixture (Merck Silica Gel 60; 230 - 400 mesh, 150 g) with CH₃OH:CHCl₃ (3 ;97) as eluent, separated 3 from a mixture with the less polar component (2.5 g, Rf = 0.18).
- Chromatography (Merck Silica Gel 60; 230 - 400 mesh, 75 g) of this mixture with Et₂O as eluent, and crystallization from Et₂O: hexane afforded 53(0.81 g, 3.7%) as a white crystalline solid, mp = 80 - 81°C (sharp).
NMR: (CDCl₃) 2.83 (d, 3H, J = 7.5 Hz, -NHCH₃) , 2.6 - 3.3 (m, 4H, -CH₂CH₂-, 3.83 (s, 3H, -OCH₃), 6.33 (s, 1H, C₄-H), 6.7 - 7.4 (m, 4H, aromatic), 7.55 (q, J = 7.5 Hz, 1H, -NHCH₃); IR (KBr) 3200, 1740; MS (20 eV EI), m/e 356, 339 (100%), 311, 297. Anal. Calcd. for C₂₀H₂₀ClN₃O₃:C,62.25;H,5.22;N,10.89
Found; C,62.31;H,5.21;N,10.88. - Following the procedure of Example 5, but substituting glycine for methylhydroxylamine hydrochloride afforded 66 (1.98 g, 67.4%), as a white crystalline solid, melting point = 185.5 - 187.5°C.
NMR (DMSO-d₆) 2.4 - 2.7 (m, 2H, -CH₂CH₂CON-), 2.7 - 3.0 (m, 2H, -CH₂CH₂CON-), 3.78 (s, 3H, -OCH₃), 3.78 (d, J = 5.5 Hz, 2H, -NHCH₂COOH), 6.53 (s, 1H, C₄-H), 6.7 - 7.6 (m, 8H, aromatic), 8.29 (broad t, J = 5.5 Hz, 1H, CONH-CH₂COOH) ; IR (KBr) 3360, 1725, 1665; MS, m/e 413 (M⁺), 311 (100%).
Anal. Calcd. for C₂₁H₂₀ClN₃O₇:C,60.94;H,4.87;N,10.15
Found:C,60.64;H,4.87;N,10.01. - Following the procedure described in Example 5 but substituting compound 17 for compound 12 afforded 67 (1.24 g, 78.0%) as a white crystalline solid, mp = 155 156.5°C.
NMR (CDCl₃) δ 2.5 - 3.5 (m, 4H, -CH₂CH₂-), 3.20 (s, 3H, -N(CH₃)OH), 6.33 (s, 1H, C₄H), 7.0 - 7.7 (m, 9H, aromatic). 10.37 (broad s, 1H, -N(CH₃) OH); IR (KBr): 3120, 1650; MS, m/e 355 (M⁺), 309 (100%).
Anal. Calcd. for C₁₉H₁₈ClN₃O₂:C,64.13;H,5.10;N,11.81
Found:C,64.17;H,5.45;N,11.51. - Following the procedure described in Example 5, but substituting compound 30 for compound 12 afforded 45 (1.21 g, 83%) as an off-white crystalline solid, mp = 151 - 154°C.
NMR (CDCl₃) 2.7 - 3.5 (m, 4H, -CH₂CH₂-), 3.20 (broad s, 3H, -NCH₃), 3.83 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic) 10.4 - 10.9 (broad s, 1H, -NOH); IR (KBr): 3140, 1650; MS (20 eV EI, m/e 369 (M⁺), 340, 323 (100%).
Anal. Calcd. for C₂₀H₂₀FN₃O₃:C,65.03;H,5.46;N,11.38
Found:C,64.87;H,5.59;N,11.05. -
- To a solution of the acid 12 (0.97 g, 2.72 mM) in THF (20 ml) at 0°C, was added one drop of DMF (catalyst) and oxalyl chloride (0.28 ml, 3.26 mM). After 0.5 hour the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to remove any excess oxalyl chloride, and the remaining crude acid chloride, of acid 12, was taken up in THF (10 ml).
To a solution of hydroxylamine hydrochloride (0.28 g, 4.08 mM) and Et₃N (1.52 ml, 10.9 mM) in THF:H₂O (10 ml:5 ml) at 0°C, was added the crude acid chloride solution, dropwise over a 5 minutes period. The cooling bath was removed, and the reaction mixture was stirred for 1 hour, diluted to 100 ml volume with EtOAc, washed with H₂O, dried (MgSO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O afforded 29 (0.88 g, 87%) as a white crystalline solid, mp = 154 - 156°C.
NMR (CDCl₃) 2.4 - 3.4 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.3 - 7.5 (m, 9H, aromatic and -NH-). IR (KBr): 3260, 1665; MS, m/e 371 (M⁺), 353, 339, 311, 298 (100%).
Anal. Calcd. for C₁₉H₁₈ClN₃O₃:C,61.37;H,4.88;N,11.30
Found:C,61.36;H,5.05;N,10.97. - To a solution of the acid12 (0.99 g, 2.77 mM) in THF (30 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.29 ml, 3.33 mM). After stirring for 0.5 hour the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to a volume of 10 ml, and added dropwise to a solution of N-(tert-butyl) hydroxylamine (HCl) (0.52 g, 4.16 mM) and Et₃N (1.56 ml, 11.1 mM) in THF:H₂O (12 ml:6 ml) at 0°C. The reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo. The residue was combined with that from a similar run on a 2.72 mM scale.
- Chromatography (Merck Silica Gel 60; 230 - 400 mesh, 72 g) with Et₂O:hexane (4:1) as eluent afforded 57, crystallized from cold Et₂O:hexane (1.19 g, 51%) as a white crystalline solid, mp = 73 -74.5°C and 58 recrystallized from EtOAc:Et₂O (0.63g, 27%) as a white crystalline solid, mp = 137 - 138°C.
- Compound 57, NMR (CDCl₃) 1.10 (s, 9H, -C(CH₃)₃), 2.7 - 3.4 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 6.32 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic); IR (KBr) 3480, 1730; MS (20eV EI), m/e 339 (100%), 311, 297.
Anal. Calcd. for C₂₃H₂₆ClN₃O₃:C,64.55;H,6.12;N,9.82 Found:C,64.41;H,6.19;N,9.71. - Compound 58, NMR (CDCl₃) 1.25 (s, 9H, -C(CH₃)₃), 2.7 - 3.4 (m, 4H, -CH₂CH₂-), 3.83 (s, 3H, -OCH₃), 6.33 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic), 10.08 (s, 1H, -N-OH). IR (KBr) 3460, 3130, 1620, 1590; MS (20eV EI), m/e 427 (M⁺), 339 (100%), 311, 297.
Anal. Calcd. for C₂₃H₂₀ClN₃O₃:C,64.55;H,6.12;N,9.82
Found:C,64.62;H,6.38;N,9.72. - To a suspension of pyridinium chlorochromate (10.02 g, 46.5 mM) in CH₂Cl₂ (500 ml) was added the alcohol 2, (5.09 g, 15.5 mM). After stirring overnight, the reaction mixture was concentrated in vacuo to a volume of about 200 ml, and diluted to 1 liter with Et₂O. This solution was filtered through celite, and the filter cake was washed with Et₂O (2 × 200 ml). The filtrate and the washes were combined and concentrated in vacuo. Chromatography (120g, Baker silica gel) of the residue with Et₂O:hexane (2:1) as eluent, and crystallization from Et₂O afforded pure 11,0.88 g, 17%) as a white crystalline solid, mp = 101 - 102°C.
NMR (CDCl₃) 2.8 - 3.2 (m, 4H, -CH₂CH₂CHO), 3.85 (s, 3H, -OCH₃), 6.32 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic), 9.93 (t, J = 1Hz, 1H, -CHO); IR (KBr) 1715; MS, m/e 340 (M⁺), 312 (100%).
Anal. Calcd. for C₁₉H₁₇ClN₂O₂:C,66.96;H,5.03;N,8.22
Found:C,66.72;H,5.12;N,8.13. - To a solution of hexamethyldisilazane (5.25 ml, 24.9 mM) in THF (125 ml) at +5°C was added 1.46 M n-butyl lithium (n-BuLi) (16.3 ml, 23.8 mM). The cooling bath was removed after 15 minutes and (4-carboxybutyl)triphenylphosphonium bromide (5.17 g, 11.7 mM) was added. Stirring was continued for 45 minutes and the aldehyde 11 (3.61 g, 10.6 mM) was added. After stirring for 1 hour, the reaction solution was diluted to a 600 ml volume with EtOAc and extracted with H₂O (2 × 200 ml). The extracts were combined, acidified with 3N HCl, and extracted with EtOAc (2 × 200 ml). The EtOAc extracts were combined, dried (Na₂SO₄), filtered and concentrated in vacuo. Chromatography of the remaining residue (Baker silica gel, 160 g) with Et₂O as eluent afforded the acid (3.39 g, 75%) as a clear yellow oil.
- To the neat acid (0.57 g, 1.34 mM) was added a 1.00 N NaOH solution (1.34 ml, 1.34 mM) and a small amount of water. After stirring overnight, the reaction solution was lyophilized to afford 32 (0.60 g, 95%) as a white solid.
Acid, NMR (CDCl₃) 1.4 - 3.1 (m, 10H, -CH₂CH₂CH=CH(CH₂)₃ COOH), 3.80 (s, 3H, - OCH₃), 5.2 - 5.7 (m, 2H, -CH=CH-), 6.33 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic); MS (20 eV EI) , m/e 426 (M+2), 424 (M⁺), 365, 351, 337, 298 (100%).
Compound 32, NMR (CD₃OD) 1.4 - 3.1 (m, 10H, -CH₂CH₂CH=CH(CH₂)₃-), 3.80 (s, 3H, -OCH₃), 5.2 - 5.7 (m, 2H, -CH=CH-) , 6.45 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic); IR (KBr) 3440, 1565; MS, m/e 423 (M-Na).
Anal. Calcd. for C₂₄H₂₄ClN₂NaO₃(1.25 H₂O):C,61.40;H,5.69;N,5.97
Found:C.61.60;H,5.46;N,5.51. - Following the procedure described in Example 5, but substituting the acid for 12 afforded 41 (0.94 g, 62%) as a clear colorless oil.
NMR (CDCl₃) 1.5 - 3.5 (m, 14H, -(CH₂)₂-CH=CH-(CH₂)₃CON(CH₃)OH, 3.80 (s, 3H, -OCH₃), 5.3 - 5.7 (m, -CH=CH-, 2H), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat): 3160, 1630; MS (20 eV EI), m/e 455 (M+2), 453 (M⁺), 407, 379, 365, 298 (100%).
Anal. Calcd. for C₂₅H₂₈ClN₃O₃:C,66.14;H,6.22;N,9.26
Found:C,65.78;H,6.55;N,8.93. - To a solution of the acid 12 (1.01 g, 2.83 mM) in THF (25 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.30 ml, 3.40 mM). After 0.5 hours the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to remove the excess oxalyl chloride, and the remaining acid chloride was diluted with THF (25 ml) and cooled to 0°C. To this solution diethylamine (1.17 ml, 11.32 mM) was added dropwise over a 5 minute period. After stirring for 1 hour, the reaction mixture was diluted to 100 ml with Et₂O, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo. Crystallization from Et₂O afforded 28 (0.98 g, 84%) as a yellow crystalline solid, mp = 111 - 112°C.
NMR (CDCl₃) 1.13, 1.17 (2t, J = 7Hz, 6H, -N(CH₂CH)₂), 2.5 - 3.8 (m, 8H, -CH₂CH₂- and -N(CH₂CH₃)₂), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 1630; MS (20eV EI), m/e 411 (M⁺), 311 (100%).
Anal. Calcd. for C₂₃H₂₆ClN₃O₂:C,67.06;H,6.36;N,10.20
Found:C,67.14;H,6.34;N,9.95. - Following the procedure of Example 17, but substituting NH₄OH, 4-aminophenol,
O,N-dimethylhydroxylamine hydrochloride, 2-aminophenol, 2-aminothiophenol, 2-aminopyridine and ethanolamine for diethylamine gave the compounds of Table 3.
-
- Compound 1 (1.00 g, 3.20 mM), acetic anhydride (1.0 ml, 11 mM), pyridine (1.0 ml, 12 mM) and CH₂Cl₂ (30 ml) were admixed and the admixture so formed was stirred overnight at room temperature, poured into H₂O (150 ml) and extracted with CH₂Cl₂ (25 ml). The extracts were dried (Na₂SO₄), filtered and concentrated to an oil (1.1 g). Chromatography (silica gel 60; 70 - 230 mesh, 150 g) and elution with Et₂O afforded 1.10 g (94%) of 7 as a colorless oil.
NMR (CDCl₃) 2.05 (s, 3H, CH₃CO), 1.8 - 2.4 (m, 2H, -CH₂CH₂CH₂), 2.8 (dist t, J ≃ 8Hz, CH₂-), 4.2 (t, 2H, J = 6, Ch₂O), 6.32 (s, 1H, C₄-H), 7.1 - 7.5 (m, 9H, aromatic);
IR (neat) 2960, 1740, 1600; MS, m/e 354 (M⁺), 311, 281, 268 (100%).
Anal. Calcd. for C₂₀H₁₉ClN₂O₂:C,67.69;H,5.40;N,7.89
Found:C,67.78;H,5.36;N,8.07. - To a suspension of NaH (0.135 g of 60% oil suspension, 3.37 mM) in THF (10 ml) at +5°C was added a solution of 2 (1.05 g, 3.06 mM) in THF (20 ml). After stirring for 30 minutes, methyl iodide (MeI) (0.21 ml, 3.37 mM) was added and the reaction mixture was left to stir overnight. After quenching with CH₃OH, the reaction mixture was concentrated in vacuo, the residue was taken up in EtOAc, washed with H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography (40g, Baker silica gel) with Et₂O as eluent afforded 24 (0.98 g, 90%) as a clear yellow oil.
NMR (CDCl₃) 1.8 - 2.4 (m, 2H,
-CH₂CH₂CH₂OCH₃), 2.6 - 3.0 (m, 2H,
-CH₂CH₂CH₂OCH₃), 3.35 (s, 3H, -CH₂OCH₃), 3.48 (t, J = 7Hz, 2H, -CH₂CH₂OCH₃), 3.78 (s, 3H, aromatic -OCH₃), 6.28 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat) 1250, 830; MS, m/e 357 (M+1, 100%), 323 298.
Anal. Calcd. for C₂₀H₂₁ClN₂O₂:C,67.31;H,5.93;N,7.85
Found:C,67.15;H,6.07;N,7.77. - To a solution of methyl magnesium bromide (MeMgBr) (2.20 ml, 7.04 mM) in Et₂O (15 ml) at 0°C was added a solution of the aldehyde 11 (1.60 g, 4.69 mM) in Et₂O (70 ml) dropwise over a 30 minute period. After stirring for 1 hour the reaction was quenched with a saturated, aqueous NH₄Cl solution. The reaction mixture was partitioned between EtOAc and H₂O. The EtOAc solution was dried (MgSO₄), filtered, and concentrated in vacuo. Chromatography (65g, Baker 40 gm silica gel) of their residue with Et₂O as eluent afforded 20 (1.33 g, 79%) as a clear light yellow oil.
NMR (CDCl₃) 1.25 (d, J = 6Hz, 3H, -CH(OH)-CH₃) 1.6 - 2.2 (m, 2H, -CH₂ -CH(OH)-), 2.2 -2.8 (m, 1H, -OH), 2.83 (t, J = 7Hz, 2H, CH₂), 3.78 (s, 3H, -OCH₃), 3.7 - 4.2 (m, 1H, -CH₂-CH(OH)-CH₃), 6.27 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat) 3380; MS, m/e 356 (M⁺), 341, 312, 311, 298 (100%). Anal. Calcd. for C₂₀H₂₁ClN₂O₂:C,67.31;H,5.93;N,7.85
Found:C,67.38;H,6.35;N,7.61. - To a suspension of pyridinium chlorochromate (3.65 g, 16.93 mM) in CH₂Cl₂ (20 ml) was added the alcohol 20, (3.02 g, 8.46 mM) in CH₂Cl₂ (15 ml). After stirring for 4 hours, the reaction solution was decanted from the chromium precipitates that were washed with EtOAc (2 × 150 ml). The reaction solution and the washes were combined, filtered through florosil, and concentrated in vacuo. Chromatography (120g, Baker 40 gm silica gel) with Et₂O:hexane (1:1 to 100% Et₂O) as eluent, followed by crystallization from Et₂O:hexane afforded 23,2.09 g, 70%) as a white crystalline solid, mp = 85 - 86°C.
NMR (CDCl₃) 2.20 (s, 3H, -CO-CH₃), 2.7 - 3.2 (m, 4H, -CH₂CH₂-), 3.78 (s, 3H -OCH₃), 6.25 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 1715; MS, m/e 355 (M+1), 321, 311.
Anal. Calcd. for C₂₀H₁₉ClN₂O₂:C,67.70;H,5.40;N,7.90
Found:C,67.41;H,5.24;N,7.90. - To a solution of MeMgBr (1.32 ml of 3.2 M, 4.23 mM) in THF (15 ml) at 0°C , was added a solution of the ketone 23, (1.00 g, 2.82 mM) in THF (25 ml) dropwise over a 20 minute period. After stirring for 1 hour, the reaction mixture was quenched with a saturated NH₄Cl solution, diluted to a 100 ml volume with Et₂O, washed with H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography of the residue (Baker silica gel, 45 g) with Et₂O as eluent, afforded 27, (0.68 g, 80% corrected for recovered starting material) as a colorless oil.
NMR (CDCl₃) 1.30 (s, 6H, -C(CH₃)₂OH), 1.7 - 2.2 (m, 2H, CH₂C-OH), 2.2 - 2.7 (broad s, 1H, -OH), 2.7 - 3.1 (m, 2H, CH₂), 3.78 (s, 3H, -OCH₃), 6.25 (s, 1H, C₄-H), 6.6 - 7.4 (m, 8H, aromatic); IR (neat) 3390, 1250; MS (20 eV EI), m/e 370 (M⁺), 355, 312 (100%), 311, 298.
Anal. Calcd. for C₂₁H₂₃ClN₂O₂:C,68.01;H,6.25;N,7.55
Found:C,67.80;H,67.80;H,6.30;N,7.24. - To a solution of the aldehyde 11 (1.00 g, 2.93 mM) in EtOH (30 ml) was added hydroxylamine hydrochloride (0.31 g, 4.40 mM) and pyridine 0(.47 g, 5.87 mM). After stirring overnight at room temperature, the reaction mixture was concentrated in vacuo. The remaining residue was taken up in CH₂Cl₂, washed H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O:hexane afforded 26, (0.67 g, 64%) as a white crystalline solid, mp = 134 - 135°C.
NMR (CDCl₃) 2.5 - 3.3 (m, 5H, -CH₂CH₂- and =N-OH), 3.78 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.5 - 7.4 (m, 9H, aromatic and -CH₂-CH=N-OH); IR (KBr) 3210; MS (20 eV EI), m/e 355 (M⁺), 338 (100%), 311, 297.
Anal. Calcd. for C₁₉H₁₈ClN₃O₂:C,64.13;H,5.10;N,11.81
Found:C,63.79;H,4.93;N,11.53. - To a solution of hexamethyldisilazane (0.70 ml, 3.34 mM) in THF (30 ml) at +5°C was added 1.55M n-BuLi (1.97 ml, 3.05 mM). The cooling bath was removed and after 15 minutes tridecyltriphenyl phosphonium bromide (1.68 g, 3.20 mM) was added. After stirring for 0.5 hour, the aldehyde 11 (0.99g, 2.90 mM) was added, the reaction mixture was stirred for an additional 30 minutes, and concentrated in vacuo. The residue was taken up in Et₂O:hexane (1:1), filtered, and concentrated in vacuo to afford crude 33 (1.42 g). Chromatography (Baker silica gel, 55 g) with Et₂O:hexane (1:2) as eluent afforded 33, (0.95 g, 65%) as a clear colorless oil.
NMR (CDCl₃) 0.7 - 3.1 (m, 29H,
-CH₂CH₂CHCH(CH₂)₁₁CH₃), (3.80 (s, 3H, -OCH₃),
5.3 - 5.7 (m,2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.6 - 7.5 (m, 8H, aromatic); IR (neat) 2940, 2860; MS (20 eV EI), 508 (M+2), 506 (M⁺), 449, 351, 338, 298 (100%).
Anal. Calcd. for C₃₂H₄₃ClN₂O:C,75.78;H,8.55;N,5.52
Found:C,75.54;H,9.03;N,5.44. - To a suspension of pyridinium chlorochromate (6.29 g, 29.2 mM) in CH₂Cl₂ (40 ml) was added the alcohol 2, (5.00 g, 14.6 mM) in CH₂Cl₂ (30 ml). After stirring for 4 hours, the reaction solution was decanted from the chromium residue on the sides of the reaction vessel. This residue was washed with EtOAc (2 × 200 ml), and the washes were combined with the reaction solution, filtered through florisil, and concentrated in vacuo. Crystallization from Et₂O afforded the crude aldehyde 11 (4.20 g, 84%) contaminated with the dimer ester 16.
- To a solution of hexamethyldisilazane (1.07 ml, 5.06 mM) in dry THF (50 ml) at +10°C was added n-BuLi (2.98 ml, 4.62 mM). The cooling bath was removed, and after 15 minutes benzyltriphenyl phosphonium chloride (1.88 g, 4.84 mM) was added. After 45 minutes the crude aldehyde 11 (1.50 g, 4.40 mM) in THF (10 ml) was added, the reaction mixture was stirred for an additional 30 minutes and concentrated in vacuo. The residue was taken up into Et₂O (150 ml), filtered, and concentrated in vacuo.
Chromatography of this residue (Baker silica gel, 85 g) with Et₂O:hexane (1:1 to 100% Et₂O) afforded the E olefin 14, the E/Z olefins 15, and dimer ester 16. Compound 14 was crystallized from Et₂O:hexane. All products were combined with those of an equivalent run using the same procedure on a 2.93 mM scale of the aldehyde 11. This afforded the E olefin 14, (1.33 g, 44%) as a white crystalline solid, mp = 93 - 95°C, the mixed E/Z olefin 15, 7:3 Z:E (1.12 g, 37%) as a clear colorless oil; and dimer ester 16 (0.40 g, 8.0%). - Compound 14 NMR (CDCl₃) 2.4 - 3.2 (m, 4H, -CH₂çH₂-), 3.80 (s, 3H, OCH₃), 6.2 - 6.7 (m, 2H, CH=CH), 6.30 (s, 1H, C₄-H), 6.7 - 7.6 (m, 13H, aromatic); IR (KBr) 1245; MS, m/e 414 (M⁺), 310, 297 (100%).
Anal. Calcd. for C₂₆H₂₃ClN₂O:C,75.26;H,5.59;N,6.75
Found:C,75.45;H,5.77;N,6.77. - Compound 15, NMR (CDCl₃) 2.5 - 3.2 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, COH₃), 5.5 - 6.7 (m, 2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.7 - 7.6 (m, 13H, aromatic); IR (neat) 1250; MS, m/e 414 (M⁺), 311, 297, (100%).
Anal .Calcd. for C₂₆H₂₃ClN₂O:C,75.26;H,5.59;N6.75
Found:C,74.86;H,5.96;N,6.61. - To a solution of the carboxylic acid 12 (0.40 g, 1.12 mM) in THF (10 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.12 ml, 1.35 mM). After stirring for 15 minutes the cooling bath was removed and stirring was continued for 1 hour The reaction mixture was concentrated in vacuo (to remove the excess oxalyl chloride), taken up in THF (10 ml), and cooled to 0°C. To this solution was added the alcohol 2 (0.38 ml, 1.12 mM) and Et₃N (0.47 ml, 3.36 mM). After 15 minutes the cooling bath was removed and stirring was continued for 1 hour. The reaction mixture was diluted to 50 ml with Et₂O, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo Chromatography (Baker silica gel, 45 g) with Et₂O:hexane (9:1) as eluent, afforded 16 (59%) as a white semi-solid.
NMR (CDCl₃) 1.8 - 2.4 (m, 2H, -CH₂CH₂CH₂-), 2.5 - 3.3 (m, 6H,
-CH₂-CH₂CH₂OCOCH₂-CH₂-), 3.80 (s, 6H, 2-OCH₃),
4.25 (t, J = 6.5Hz, 2H, -CH₂CH₂OCO-), 6.27 + 6.33 (2s, 2H, 2× C₄-H), 6.7 - 7.5 (m, 16H, aromatic); IR (KBr) 1730; MS (DCI), 681 (M+1), 325.
Anal. Calcd. for C₃₈H₃₄Cl₂N₄O₄:C,66.96;H,5.03;N,8.22
Found:C,66.60;H,4.90;N,7.83. - To a solution of hexamethyldisilazane (1.08 ml, 5.13 mM) in THF (50 ml) at +5°C was added n-BuLi (3.02 ml of 1.55 M, 4.68 mM). After 15 minutes
(4-carbomethoxyphenyl)triphenyl phosphonium chloride (2.19 g, 4.91 mM) was added, and the cooling bath was removed. After 30 minutes the aldehyde 11 (1.52 g, 4.46 mM) in THF (10 ml) was added, and the reaction mixture was stirred for an additional 0.5 hour. Concentration in vacuo of the reaction mixture and chromatography (Baker silica gel, 80 g) with Et₂O:hexane (1:1 to 100% Et₂O) as eluent afforded 25. Recrystallization from Et₂O afforded pure 25 (1.10 g, 48%) as a white crystalline solid, mp = 126 - 128°C.
NMR (CDCl₃) 2.5 - 3.1 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 3.90 (s, 3H, -COOCH₃), 5.8 - 6.7 (m, 2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.7 - 8.2 (m, 12H, aromatic); IR (KBr) 1725; MS, m/e 472 (M⁺), 441, 297 100%).
Anal. Calcd. for C₂₈H₂₅ClN₂O₃:C,71.10;H,5.33;N,5.92
Found:C,71.30;H,5.22;N,5.97. - To a solution of the acid 12 (0.98 g, 2.75 mM) in Et₂O (10 ml) and CH₂Cl₂ (15 ml) at 0°C, was added a CH₂N₂ solution in Et₂O (prepared from N-nitroso-N-methylurea, 40% KOH/Et₂O) until a persistent yellow color was observed in the reaction mixture. The reaction mixture was dried (MgSO₄), filtered and concentrated in vacuo. Crystallization from EtOAc:hexane afforded 19 (0.85 g, 83%) as a white crystalline solid, mp = 117 - 118°C.
NMR (CDCl₃) 2.5 - 3.4 (m, 4H, -CH₂CH₂-), 3.70 (s, 3H, -COOCH₃), 3.80 (s, 3H, -OCH₃), 6.28 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatics); IR (KBr) 1730; MS, m/e 370 (M⁺), 339, 311 (100%).
Anal. Calcd. for C₂₀H₁₉ClN₂O₃:C,64.77;H,5.16;N,7.56
Found:C,64.47;H,5.15;N,7.65. - 5-(4-Chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole (1.71 g, 0.005 moles) and 2,2,6-trimethyl-1,3-dioxen-4-one (0.71 g, 0.005 moles) were disolved in 100 ml of xylenes. The solution was stirred under reflux for 16 hours. At the time, the solution was cooled to room temperature, and concentrated in vacuo to a yellow oil. The oil was flash chromatographed on silica gel to afford 59 (1.7 g, 80%) as a pale yellow oil.
NMR (CDCl₃) 1.8 - 2.4 (m, 2H, CH₂CH₂CH₂), 2.1 (s, 3H, COCH₃), 2.8 (t, 2H, J = 7Hz, CH₂), 3.48 (s, 2H, COCH₂CO), 3.85 (s, 3H, OCH₃), 4.25 (t, 2H, J = 7Hz, CH₂OCO), 6.25 (s, 1H, C₄-H), 6.9 (d, J = 8Hz, 2 aromatic H), 7.0 - 7.4 (m, 6H, aromatic H); IR (neat) 1750, 1725; MS, m/e 426 (M⁺), 341.
Anal. Calcd. for C₂₃H₂₃ClN₂O₄:C,64.71;H,5.43;N,6.56
Found:C,64.97;H,5.67;N,6.13. - To a suspension of LiAlH₄ (0.13 g, 3.5 mM) in THF (15 mL) was added a solution of the amide 31, (1.00 g, 2.81 mM) in THF (15 ml), dropwise, keeping the reaction temperature below reflux. The reaction mixture was heated to reflux, and refluxed for 17 hours, when it was quenched with 0.13 ml H₂O, 0.13 mL 20% NaOH solution and an additional 0.39 ml H₂O. The reaction mixture was filtered and concentrated in vacuo. The remaining residue was taken up into EtOAc (50 mL) and extracted with a 1.0 N HCl solution (2×25 mL). The aqueous extracts were combined and washed with EtOAc (25 mL), neutralized with a 2N NaOH solution, and extracted with EtOAc (2×50 mL). The organic extracts were dried (Na₂SO₄), filtered and concentrated in vacuo to afford the title compound (0.86 g, 90%) as a light yellow oil.
NMR (CDCl₃) 1.6-2.3 (m, 4H, -CH₂CH₂CH₂NH₂), 2.6-3.1 (m, 4H, -CH₂CH₂CH₂NH₂), 3.78 (s, 3H, -OCH₃), 6.27 (s, 1H, C₄-H), 6.6-7.5 (m, 8H, aromatic); IR (neat) 3380, 1520; MS (DCI), m/e 344( MH⁺ +2), 342 (MH⁺, 100%).
Anal. Calcd. for C₁₉H₂₀ClN₃O:C,66.76;H,5.90;N,12.29.
Found:C,66.70;H,5.97;N,11.83. - To a suspension of compound 31, (7.75 g, 21.8 mM) in dry benzene (400 mL) was added SOCl₂ (4.78 mL, 65mM). The reaction mixture was heated to reflux for three days and then cooled at 0°C. Any excess SOCl₂ was decomposed with ice water. 50 mL of H₂O was added to the reaction mixture which was then neutralized with 50% NaOH, washed with H₂O (2×50mL), dried (Na₂SO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O, Hexane afforded the title compound (6.43 g, 87%) as a light yellow crystalline solid, mp = 107-109°C.
NMR (CDCl₃) 2.4=3.2 (m, 4H, -CH₂CH₂-), 3.82 (s, 3H, OCH₃), 6.41 (s, 1H, C₄-H), 6.7-7.5 (m, 8H, aromatic); IR (KBr) 2250, 1510; MS(EI) m/e 339 (M+2, lCl), 337 (M⁺, 100%).
Anal. Calcd. for C₁₉H₁₆ClN₃O:C,67.55;H,4.77;N,12.44
Found:C,67.23;H,4.88;N,12.21 - To a solution of the hydroxamic acid 3 (5.0 g, 12.96 mM) in dry pyridine (13 ml) was added succinic anhydride (1.3 g, 12.99 mM) in pyridine (5 ml) and the resulting solution was stirred for 72 hours. The pyridine was removed in vacuo and the residue was triturated with hexane and recrystallized from Et₂O to afford pure 34 (6.21 g, 98%) as a white solid, mp = 146-147°. MS, m/e 485(M⁺).
Anal. Calcd. for C₂₄H₂₄ClN₃O₆: C,59.32; H,4.98; N,8.65
Found: C,59.68; H,4.97; N,8.75 -
- Compound 3 (6.0 g, 15.55 mM) was added to a suspension of N,N-dimethyl-glycine (1.61 g, 15.61 mM) and NʹNʹ-dicyclohexylcarbodiimide (3.21 g, 15.55mM) in dry pyridine (22 ml) under nitrogen and stirred for 44 hours. The solvent was removed in vacuo and the residue triturated with CH₂Cl₂, filtered, and the filtrate evaporated to dryness. Recrystallization from CH₂Cl₂/Et₂O afforded pure 35 (6.8 g, 93%) as a white solid, mp = 103-104°, MS, m/e 470 (M⁺).
Anal. Calcd. for C₂₄H₂₇C1N₄O₄: C,61.20; H,5.78; N,11.90
Found: C,61.26; H,5.94; N,11.79 - The oxalate salt of 35 was synthesized as the trihydrate as a white solid, mp = 114-115°. Anal. Calcd. for C₂₄H₂₇ClN₄O₄·C₂H₂O₄·3H₂O:C,50.77;H,5.74;N,9.11
Found:C,50.68;H,5.73;N,8.64 -
- To a solution of 3 (7.0 g, 18.14 mM) in anhydrous THF (125 ml) was added methylmorpholine (1.99 ml, 18.1 mM) and the resulting solution was cooled to -10° C under nitrogen. Chloroacetyl chloride (1.44 ml, 18.1 mM) was added and stirred for 10 minutes, filtered and the filtrate concentrated in vacuo. The residue was recrystallized from Et₂O to afford pure 36 (5.7 g, 68%) as a white solid, mp = 110-111°. MS, m/e 461 (M⁺).
Anal. Calcd. for C₂₂H₂₁Cl₂N₃O₄: C,57.15; H,4.58; N,9.09
Found: C,57.42; H,4.55; N,8.99. -
-
- The acid 12 (3.57 g, 10 mM) and N-bromosuccinimide (1.78 g, 10 mM) were dissolved in a mixture of CCl₄ (150 ml) and CHCl₃ (20 ml) and allowed to stir for 16 hours. The solvents were evaporated in vacuo and the residue was dissolved in CHCl₃, washed with H₂O, dried (Na₂SO₄), filtered and evaporated to give an oil which was crystallized from Et₂O to afford pure 37 (2.18 g, 50%) as a white solid, mp = 147.5-148°. MS ,m/e 435 (MH⁺).
Anal. Calcd. forC₁₉H₁₆BrClN₂O₃: C,52.37; H,3.70; N,6.43
Found: C,52.58; H,3.69; N,6.27. - Substitution of N-chlorosuccinimide for N-bromosuccinimide gave the corresponding 4-chloro derivative as a white solid, mp = 123.5-124.5°. MS, m/e 391(MH⁺) (Compound Number 182)
Anal. Calcd. for C₁₉H₁₆Cl₂N₂O₃·1/4H₂0: C,57.66; H,4.20; N,7.08
Found: C,57.78; H,4.12; N,6.96. -
- Substituting Compound 2 for the acid 12 in Example 37 afforded 4-bromo-5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl)pyrazole, as an off-white solid, 87%, mp = 118.5-120°. MS, m/e 420 (M⁺) (Compound Number 183).
Anal. Calcd. for C₁₉H₁₈BrClN₂O₂: C, 54.11; H, 4.30; N. 6.64
Found: C, 54.20; H, 4.35; N. 6.59 - Following a similar procedure, but employing N-chlorocuccinimide gave 4-chloro-5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl)pyrazole as a tan solid; mp = 113-115°. MS, m/e 376 (M⁺) (Compound Number 184). Anal. Cald. for C₁₉H₁₈Cl₂N₂O₂: C, 60.49; H, 4.81; N, 7.43
Found: C, 60.30; H, 4.82; N, 7.36 - To a solution of the oxime 26 (2.70 g, 7.59 mM) in MeOH (50 ml), containing methyl orange (2 mg) as as indicator, was added a solution of NaBH₃CN (0.52 g, 8.4 mM) in MeOH (20 ml), and a solution of 2N HCl, simultaneously, at such a rate to maintain a pH of 3 to 4. The reaction was stirred for 3 hours at room temperature, acidified to pH 1 and concentrated in vacuo. The residue was diluted with H₂O (100 ml), adjusted to pH 8.5 with 5N NaOH, and extracted with EtOAc. The extracts were combined, dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was chromatographed on Merck Silica Gel 60 (90 g, 230-400 mesh) with EtOAc:MeOH (9:1) as eluent. Crystallization from Et₂O afforded pure 38 (1.64 g, 60%) as a white solid, mp = 91-93°. MS, m/e 357 (M⁺).
Anal. Calcd. for C₁₉H₂₀ClN₃O₂: C,63.77; H,5.63; N,11.74
Found: C,63.63; H,5.74; N,11.63. - To a solution of hydroxylamine 38 (1.25 g, 3.49 mM) and Et₃N (0.97 ml, 6.9mM) in THF (35 ml) was added acetyl chloride (0.25 ml, 3.5 mM) and the reaction mixture stirred for 1 hour, diluted with EtOAc (165 ml), washed with H₂O, dried (Na₂SO₄), filtered and concentrated in vacuo to give a residue which was recrystallized from EtOAc:Et₂O to afford pure 39 (1.06 g, 76%) as a white crystalline solid, mp = 121-123°. MS, m/e 399 (M⁺).
Anal. Calcd. for C₂₁H₂₂ClN₃O₃: C,63.07; H,5.55; N,10.51
Found: C,62.83; H,5.95; N,10.43. -
- Following a similar procedure to that of Example 39, but employing ethyl oxalyl chloride in place of acetyl chloride afforded 40 as a white foam; MS, m/e 457 (M⁺).
Anal. Calcd. for C₂₃H₂₄ClN₃O₃: C,60.33; H,5.28; N,9.18
Found: C,60.55; H,5.67; N,9.18. - To a solution of hydroxylamine.HCl (0.25 g, 3.5 mM) and the ester 7C (0.81 g, 1.8mM) in EtOH (17 ml) was added in 1N NaOEt solution (7.1 ml, 7.1 mM). After stirring for 2.5 hours the reaction mixture was acidified and concentrated in vacuo. The residue was diluted with CHCl₃, washed (H₂O), dried (Na₂SO₄), filtered and concentrated in vacuo. Crystallization from EtOAc:Et₂O afforded pure 41 as a white crystalline solid, mp = 145-146.5° MS, m/e 444 (M⁺).
Anal. Calcd. for C₂₁H₂₁ClN₄O₅·0.25 H₂O: C,56.13;H,4.82;N,12.47
Found: C,56.16;H,4.76;N,12.32. - To a solution of the acid 12 (1.0 g, 2.8 mM) in benzene (25 ml) was added Et₃N (0.39 ml, 2.8 mM) and diphenylphosphoryl azide (0.60 ml, 2.8 mM). After stirring overnight at room temperature, the reaction mixture was heated to 70°C for 1.5 hours, cooled and concentrated in vacuo.. Dioxane (2 ml), followed by a solution of concentrated HCl (0.3 ml) in dioxane (2 ml) was added, and the reaction mixture was heated to reflux for 2 hours, cooled and diluted to 50 ml with EtOAc. The organic solution was washed with 0.25N NaOH solution, and extracted with 1N HCl. The extracts were combined, basified with 5N NaOH, and extracted with EtOAc, dried, filtered and concentrated in vacuo. Crystallization from Et₂O afforded pure 42 (0.62 g, 68%) as a light yellow crystalline solid, mp= 95-97°. MS, m/e 327 (M⁺).
Anal. Calcd. for C₁₈H₁₈ClN₃O: C, 65.95; H,5.53; N,12.82
Found: C, 66.14; H,5.57; N,13.10. - To a solution of the amine 42 (3.24 g, 9.8 mM) and Et₃N (1.56 ml, 10.9 mM) in THF (100 ml) was added ethyloxalyl chloride (1.1 ml, 9.8 mM). After stirring overnight the reaction mixture was diluted to 400 ml with EtOAc, washed with H₂O,dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was chromatographed on Merck Silica Gel 60 (110 g, 230-400 mesh) with EtOAc:Hexane (3:1) as eluent. Crystallization from EtOAc:Hexane afforded pure 43 (3.6 g, 85%) as a white crystalline solid, mp = 93-94°. MS, m/e 427 (M⁺).
Anal Calcd. for C₂₂H₂₂ClN₃O₄: C,61.75; H,5.18; N,9.82
Found: C,61.56; H,5.29; N,9.78 - Following the procedure of Example 43, but substituting the amine 96of Example 32 for the amine 42 afforded 44 as a yellow oil; MS, m/e 441 (M⁺).
Anal. Calcd. for C₂₃H₂₄ClN₃O₄: C,62.51; H, 5.49; N,9.51
Found: C, 62.41; H,5.66; N,9.35. -
- To a solution of the amine 96 (0.96 g, 2.8 mM) and Et₃N (0.59 ml, 4.2 mM) in THF (25 ml) was added acetyl chloride (0.2 ml, 2.8 mM). After stirring for 1 hour the reaction mixture was diluted to 200 ml with EtOAc, washed with H₂O, dried, filtered and concentrated in vacuo. Crystallization from EtOAc:Et₂O afforded pure 45 (0.78 g, 72%) as an off-white crystalline solid, mp = 129-131°. MS, m/e 383 (M⁺).
Anal. Calcd. for C₂₁H₂₂ClN₃O₂: C,65.70; H,5.78; N,10.95
Found: C,65.85; H,6.00; N,10.88. -
- A white slurry of compound 29 of Example 12 (5.0 g, 13.45mM) in CH₂Cl₂ (200 ml) and Et₃N (1.88 ml, 13.48 mM) was cooled to -10°C under nitrogen, and treated with acetyl chloride (0.91 ml, 12.8 mM). The mixture was allowed to stir at -10°C for 45 minutes, filtered and the filtrate concentrated in vacuo to give crude product which was purified via flash column chromatography (EtOAc) and recrystallized from Et₂O to afford 46 as a white solid, mp = 110-111°. MS, m/e 413 (M⁺).
Anal. Calcd. for C₂₁H₂₀ClN₃O₄: C,60.94; H,4.87; N,10.15
Found: C,61.19; H,5.15; N, 9.77. - Following the procedure of Example 46, but employing 2 equivalents of acetyl chloride afforded 47 as a white solid, mp = 111-112°. MS, m/e 455 (M⁺). Anal. Calcd. for C₂₃H₂₂ClN₃O₅: C,60.59; H,4.86; N,9.22
Found: C,60.52; H,5.12; N,9.06.
- A solution of compound 23 (2.15 g, 6.06 mM) in EtOH (6.2 ml) and glacialacetic acid (0.2 ml) was warmed to 35° and 2-thiazolylhydrazine (0.698 g, 6.06 mM) was added. Stirring was continued for 80 minutes and the resulting brown solution was cooled to room temperature for 1 hour, then allowed to stand at -15°, filtered, and recrystallized from EtOH to afford 48 as a tan solid (1.22 g, 45%), mp = 128-129°. MS, m/e 451 (M⁺).
Anal. Calcd. for C₂₃H₂₂ClN₅S: C,61.12; H,4.91; N,15.50
Found: C,60.89; H,4.81; N,15.12. -
-
-
- To a suspension of nitrile 95 (1.0 g, 2.96 mM) in MeOH (6 ml) was added NaHCO₃ (0.50 g, 5.9 mM) and a solution of hydroxylamine.HCl (0.40 g, 5.9mM) in H₂O (5 ml). The reaction was heated to reflux for 16 hours, concentrated in vacuo and the residue partitioned between H₂O and CHCl₃. The CHCl₃ layer was dried (Na₂SO₄), filtered and concentrated in vacuo to a white foam. Crystallization from EtOAc afforded pure 49 (0.65 g, 59%) as a white crystalline solid, mp = 132-134°. MS, m/e 370 (M⁺).
Anal. Calcd. for C₁₉H₁₉ClN₄O₂·0.25 H₂0: C,60.80;H,5.24;N,14.93
Found: C,60.73;H,5.18;N,14.74. - Following the procedure of Example of 48, but substituting N-methylhydroxylamine.HCl for hydroxylamine.HCl afforded 50 as a white solid, mp = 106-110°. MS, m/e 384 (M⁺).
Anal. Calcd. for C₂₀H₂₁N₄O₂·H₂O: C,59.62;H,5.75;N,13.91
Found: C,59.62;H,5.65;N,13.61. -
- Following the procedure employed for the synthesis of the 4,6-dioxohexanoic acids of Table 2ʺ-AP, but substituting 4ʹ-methylpropiophenone for the appropriately substituted acetophenone gave the title compound 5-methyl-6-(4-methylphenyl)-4,6-dioxohexanoic acid.
-
- Following the procedure employed for the synthesis of the pyrazole propionic acids of Table 2ʺ, but substituting compound 5-methyl-6-(4-methylphenyl)-4,6-dioxohexanoic acid for the appropriate 6-aryl-4,6-diketohexanoic acid gave 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-4-methyl-3-pyrazolyl]propionic acid.
- Following the procedure of Example 5, but substituting the propionic acid compound obtained above for the acid 12 gave 3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-4-methyl-3-pyrazolyl]-N-hydroxy-N-methylpropanamide the title compound.
- Polyarthritis was induced in Lewis strain laboratory rats (weight = about 200 grams) by injection of a suspension of Mycobacterium butyricum in mineral oil into the subplantar tissue of the mammal's hind paws. On day 10 after the injection, the rats were assigned to groups, and paw volumes and body weights were recorded. Paw volumes of the contralateral, uninjected hind paw were determined by mercury plethylsmography. Per oral (p.o.) dosing began and continued for five consecutive days thereafter. On day 14 after the initial injection, approximately four hours after the final dose was administered, paw volumes and body weights were recorded and quantitated.
-
-
- The present invention has been described with respect to prefered embodiments. It will be clear to those skilled in the art that modifications and/or variations of the disclosed subject matter can be made without departing from the scope of the invention set forth herein.
Claims (15)
R₁, R₂, R₃ and R₄ are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkythio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R₁R₂ or R₃R₄, taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group;
R is a straight chained, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;
Y is hydrogen, bromo, chloro or lower alkyl;
and X is selected from the group consisting of carboxy, hydroxy, acetoxy, alkanoyloxy, lower alkoxy, lower alkyl carbonyl, oximino, cyano, amino, C(O)-R₅ and -C(O)C(O)-R₅ wherein R₅ is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR₆R₇ wherein R₆ or R₇ are the same or different and are selected from the group consisting of hydrogen and lower alkyl, or R₆ or R₇ are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, hydroxy, acyloxy, benzyloxy, 2-hydroxy lower alkyl, lower alkyl carboxy, phenyl, substituted phenyl, pyridyl, thiazolyl, dihydrothiazolyl, 5-tetrazolyl, -OCO(CH₂)nCOR₉ wherein R₉ is -OH, -ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; -OCOR₁₀ wherein R₁₀ is -CH₂NR₁₁R₁₂ wherein R₁₁ and R₁₂ are alkyl, such as methyl, cycloalkyl such as cyclohexyl, or together are a heterocyclic ring such as N-methylpiperazino, -OCOR₁₀ wherein R₁₀ is -CH₂Cl, -CH₂O-lowerakyl or t-butyl, -CH-loweralkyl-CO₂-Q, wherein Q is lower alkyl or -H, acyl such as acetyl, propionyl or butyryl; -NR₈OH wherein R₈ is hydrogen, -CO-loweralkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, SO₂-lower alkyl, -COCO₂-lower alkyl, and -COCONHOH; -NHR₁₃ wherein R₁₃ is hydrogen, -CO-lower alkyl, -CO-tbutyl, -COC₇H₁₅, -CO-phenyl, -SO₂-lower alkyl, -COCO₂-lower alkyl, -COCONHOH, -COCO₂H, COCON(lower alkyl)OH, and PO(O-lower alkyl)₂;
-C(R₁₄)=NNH-2-thiazolino, -CH(OH)R₁₄ and -C(O)R₁₄ wherein R₁₄ is hydrogen, lower alkyl, phenyl and tbutyl; -C(=NOH)NH₂ and -C(=NH)N(OH)-lower alkyl, ω-alkanoate and O-NR₈R₉ wherein R₈ and R₉ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl;
with the provisos that:
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-methylpropanamide;
5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole;
5-(4-trifluoromethylphenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole;
1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(3-hydroxypropyl) pyrazole;
sodium 8-[5-(4-chlorophenyl)-1-(4-methoxyphenyl-3-] pyrazolyl 5(Z)-octenoate.
sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl propanoate;
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] -N-tert-butyl-N-hydroxypropanamide;
N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl) -3-pyrazolyl] -propanamide;3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl] -N-hydroxy-N-methyl propanamide;
3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl] -N-methyl-N-succinyloxypropanamide;
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] -Nʹ-Nʹ-dimethylglycinyloxy-N-methylpropanamide;
N-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propyl] -N,Nʹ-dihydroxyoxamide; or
N-acetyl-N-acetoxy [5-(4-chlorophenyl)-1-(4-methoxyphenyl) -3-pyrazolyl] propanamide.
X is selected from the group consisting of carboxy, C(O)-R₅ wherein R₅ is selected from the group consisting of N(CH₃)OH, N(t-C₄H₉)OH, NHOH, ONH(CH₃) and ONH(t-C₄H₉).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT87304720T ATE97660T1 (en) | 1986-05-29 | 1987-05-28 | PHARMACOLOGICALLY ACTIVE 3-SUBSTITUTE 1,5DIARYL-PYRAZOLES AND PROCESS FOR THEIR PRODUCTION. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86799686A | 1986-05-29 | 1986-05-29 | |
US867996 | 1986-05-29 | ||
US07/042,661 US4826868A (en) | 1986-05-29 | 1987-04-29 | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
US42661 | 1997-04-04 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0248594A2 true EP0248594A2 (en) | 1987-12-09 |
EP0248594A3 EP0248594A3 (en) | 1988-11-17 |
EP0248594B1 EP0248594B1 (en) | 1993-11-24 |
Family
ID=26719497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP87304720A Expired - Lifetime EP0248594B1 (en) | 1986-05-29 | 1987-05-28 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same |
Country Status (21)
Country | Link |
---|---|
US (1) | US4826868A (en) |
EP (1) | EP0248594B1 (en) |
JP (1) | JP2512751B2 (en) |
KR (1) | KR960007163B1 (en) |
CN (1) | CN1028227C (en) |
AU (1) | AU596844B2 (en) |
CA (1) | CA1337122C (en) |
DE (2) | DE3788244T2 (en) |
DK (1) | DK170202B1 (en) |
ES (1) | ES2059377T3 (en) |
FI (1) | FI94340C (en) |
HK (1) | HK14094A (en) |
HU (1) | HU221300B1 (en) |
IE (1) | IE63856B1 (en) |
IL (1) | IL82671A0 (en) |
LU (1) | LU90829I2 (en) |
NL (1) | NL300057I2 (en) |
NO (2) | NO172236C (en) |
NZ (1) | NZ220353A (en) |
PH (1) | PH25126A (en) |
PT (1) | PT84964B (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0293220A2 (en) * | 1987-05-29 | 1988-11-30 | Ortho Pharmaceutical Corporation | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing |
EP0293221A2 (en) * | 1987-05-29 | 1988-11-30 | Ortho Pharmaceutical Corporation | Regioselective Synthesis of 1,5-Disubstituted Pyrazoles |
EP0320628A1 (en) * | 1987-11-13 | 1989-06-21 | Abbott Laboratories | Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase |
US4960787A (en) * | 1989-02-06 | 1990-10-02 | Ciba-Geigy Corporation | Certain pyrrolyl-substituted hydroxamic acid derivatives |
EP0417449A1 (en) * | 1989-07-31 | 1991-03-20 | Bristol-Myers Squibb Company | Arylpyrazole derivatives as platelet aggregation inhibitors |
US5096919A (en) * | 1989-01-05 | 1992-03-17 | Ciba-Geigy Corporation | Pyrrolylphenyl-substituted hydroxamic acid derivatives |
EP0480690A1 (en) * | 1990-10-10 | 1992-04-15 | Ciba-Geigy Ag | Aqueous ophthalmic microemulsions of tepoxalin |
EP0554829A2 (en) * | 1992-02-05 | 1993-08-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity |
FR2692575A1 (en) * | 1992-06-23 | 1993-12-24 | Sanofi Elf | Novel pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them |
WO1995013262A1 (en) * | 1993-11-12 | 1995-05-18 | Rhone-Poulenc Rorer Limited | Substituted phenyl compounds |
WO1996009292A1 (en) * | 1993-08-30 | 1996-03-28 | Ortho Pharmaceutical Corporation | 1,5-diphenyl-3-(n-hydroxycarbamoyloxyalkyl)pyrazoles |
WO1996014302A1 (en) * | 1994-11-08 | 1996-05-17 | Eisai Co., Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
WO1996038418A1 (en) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5607958A (en) * | 1990-08-20 | 1997-03-04 | Sanofi | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them |
WO1999054314A1 (en) * | 1998-04-17 | 1999-10-28 | Boehringer Ingelheim Pharma Kg | Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
US6136839A (en) * | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
WO2004037793A1 (en) * | 2002-10-24 | 2004-05-06 | Wakamoto Pharmaceutical Co., Ltd. | Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase |
WO2011147910A1 (en) * | 2010-05-27 | 2011-12-01 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
WO2011161645A1 (en) * | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
WO2011161615A1 (en) * | 2010-06-24 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
EP2861562A4 (en) * | 2012-06-14 | 2015-12-16 | Mayo Foundation | Pyrazole derivatives as inhibitors of stat3 |
US9757358B2 (en) | 2010-02-04 | 2017-09-12 | Laboratorios Del Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US9782483B2 (en) | 2010-05-21 | 2017-10-10 | Laboratories Del Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
US9789115B2 (en) | 2010-08-03 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
US9789117B2 (en) | 2011-05-18 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
US9844516B2 (en) | 2010-02-04 | 2017-12-19 | Laboratorios De Dr. Esteve | Sigma ligands for use in the prevention and/or treatment of post-operative pain |
US9914705B2 (en) | 2008-04-25 | 2018-03-13 | Laboratorios Del Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
US9931346B2 (en) | 2013-12-17 | 2018-04-03 | Laboratorios Del Dr. Esteve S.A. | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4898952A (en) * | 1987-05-29 | 1990-02-06 | Ortho Pharmaceutical Corporation | Regioselective synthesis of a 1,5-disubstituted pyrazole |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
US4956379A (en) * | 1990-02-13 | 1990-09-11 | Bristol-Myers Squibb Company | Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith |
CA2036192A1 (en) | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
US5117054A (en) * | 1991-09-26 | 1992-05-26 | Ortho Pharmaceutical Corporation | N-hydroxy, N-methyl propanamides |
US5260458A (en) * | 1991-09-26 | 1993-11-09 | Ortho Pharmaceutical Corporation | 2-oxo tetrahydrofuran compounds |
US5550147A (en) * | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5922751A (en) * | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
WO1996018399A1 (en) * | 1994-12-13 | 1996-06-20 | Euro-Celtique, S.A. | Aryl thioxanthines |
US6025361A (en) * | 1994-12-13 | 2000-02-15 | Euro-Celtique, S.A. | Trisubstituted thioxanthines |
AU4527996A (en) * | 1994-12-13 | 1996-07-03 | Euro-Celtique S.A. | Trisubstituted thioxanthines |
US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
US6075016A (en) * | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
US6191147B1 (en) | 1998-12-24 | 2001-02-20 | Ppd Discovery, Inc. | Pyrazole compounds and uses thereof |
PT1144382E (en) | 1999-08-03 | 2005-02-28 | Ortho Mcneil Pharm Inc | PROCESS FOR THE PREPARATION OF 1,5-DIARYYL-3- (SUBSTITUTED) PYRAZOLES |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
UA79804C2 (en) * | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
WO2004016741A2 (en) * | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use |
WO2004016592A1 (en) * | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
US6649638B1 (en) | 2002-08-14 | 2003-11-18 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
JP4419078B2 (en) * | 2002-12-02 | 2010-02-24 | アステラス製薬株式会社 | Pyrazole derivative |
CN100387594C (en) * | 2003-04-03 | 2008-05-14 | 麦克公司 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
KR20060030506A (en) * | 2003-07-02 | 2006-04-10 | 얀센 파마슈티카 엔.브이. | Cck-1 receptor modulators |
US20050020565A1 (en) * | 2003-07-02 | 2005-01-27 | Jones Todd K. | CCK-1 receptor modulators |
AR045536A1 (en) * | 2003-08-29 | 2005-11-02 | Ranbaxy Lab Ltd | INHIBITORS OF PHOSPHODIESTERASE TYPE -IV |
US20070060629A1 (en) * | 2003-10-17 | 2007-03-15 | Yasuhiro Imanishi | Large conductance calcium-activated k channel opener |
EP1694655A2 (en) * | 2003-11-26 | 2006-08-30 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
WO2005063716A1 (en) * | 2003-12-22 | 2005-07-14 | Janssen Pharmaceutica, N.V. | Imidazoles and their use cck-1 receptor modulators |
NZ551563A (en) * | 2004-06-30 | 2009-06-26 | Janssen Pharmaceutica Nv | Alpha,beta-unsaturated esters and acids by stereoselective dehydration |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
CA2664247A1 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
WO2008035316A2 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
US20080207659A1 (en) * | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
US20110130403A1 (en) * | 2007-03-14 | 2011-06-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
MX2009009793A (en) * | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors. |
WO2009051772A1 (en) * | 2007-10-17 | 2009-04-23 | Duke University | Geranylgeranyl transferase inhibitors and methods of making and using the same |
WO2012006068A2 (en) * | 2010-06-28 | 2012-01-12 | President And Fellows Of Harvard College | Compounds for the inhibition of cellular proliferation |
US8492424B2 (en) * | 2010-07-01 | 2013-07-23 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1946370A1 (en) * | 1969-09-12 | 1971-04-22 | Byk Gulden Lomberg Chem Fab | Pyrazole derivatives and processes for their preparation |
DE2633992A1 (en) * | 1975-08-08 | 1978-02-09 | Schering Ag | Antiinflammatory (1,4)-diphenyl-(3)-alkyl-carboxy-pyrazole - prepd. by treating corresp. (3)-halide with a cyanide, and opt. hydrolysing or reducing |
EP0014847A1 (en) * | 1979-02-19 | 1980-09-03 | MERCK PATENT GmbH | Pyrazole derivatives, pharmaceutical preparations containing them and process for their production |
EP0086450A2 (en) * | 1982-02-13 | 1983-08-24 | Hoechst Aktiengesellschaft | Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1373212A (en) * | 1970-12-07 | 1974-11-06 | Wyeth John & Brother Ltd | Pyrazole compounds |
US3974176A (en) * | 1973-08-16 | 1976-08-10 | Byk-Gulden Lomberg Chemische Fabrik Gmbh | Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them |
-
1987
- 1987-04-29 US US07/042,661 patent/US4826868A/en not_active Expired - Lifetime
- 1987-05-18 NZ NZ220353A patent/NZ220353A/en unknown
- 1987-05-27 AU AU73608/87A patent/AU596844B2/en not_active Expired
- 1987-05-27 CA CA000538137A patent/CA1337122C/en not_active Expired - Lifetime
- 1987-05-27 IL IL82671A patent/IL82671A0/en unknown
- 1987-05-27 DK DK273587A patent/DK170202B1/en active Protection Beyond IP Right Term
- 1987-05-27 NO NO872228A patent/NO172236C/en not_active IP Right Cessation
- 1987-05-28 DE DE87304720T patent/DE3788244T2/en not_active Expired - Lifetime
- 1987-05-28 EP EP87304720A patent/EP0248594B1/en not_active Expired - Lifetime
- 1987-05-28 PT PT84964A patent/PT84964B/en unknown
- 1987-05-28 IE IE140387A patent/IE63856B1/en not_active IP Right Cessation
- 1987-05-28 DE DE2001199049 patent/DE10199049I2/en active Active
- 1987-05-28 ES ES87304720T patent/ES2059377T3/en not_active Expired - Lifetime
- 1987-05-28 HU HU466/87A patent/HU221300B1/en unknown
- 1987-05-28 PH PH35317A patent/PH25126A/en unknown
- 1987-05-28 FI FI872379A patent/FI94340C/en not_active IP Right Cessation
- 1987-05-29 CN CN87103953A patent/CN1028227C/en not_active Expired - Lifetime
- 1987-05-29 JP JP62134789A patent/JP2512751B2/en not_active Expired - Lifetime
- 1987-05-29 KR KR1019870005383A patent/KR960007163B1/en not_active IP Right Cessation
-
1994
- 1994-02-24 HK HK140/94A patent/HK14094A/en not_active IP Right Cessation
-
2001
- 2001-09-10 NL NL300057C patent/NL300057I2/en unknown
- 2001-09-10 NO NO2001016C patent/NO2001016I1/en unknown
- 2001-09-10 LU LU90829C patent/LU90829I2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1946370A1 (en) * | 1969-09-12 | 1971-04-22 | Byk Gulden Lomberg Chem Fab | Pyrazole derivatives and processes for their preparation |
DE2633992A1 (en) * | 1975-08-08 | 1978-02-09 | Schering Ag | Antiinflammatory (1,4)-diphenyl-(3)-alkyl-carboxy-pyrazole - prepd. by treating corresp. (3)-halide with a cyanide, and opt. hydrolysing or reducing |
EP0014847A1 (en) * | 1979-02-19 | 1980-09-03 | MERCK PATENT GmbH | Pyrazole derivatives, pharmaceutical preparations containing them and process for their production |
EP0086450A2 (en) * | 1982-02-13 | 1983-08-24 | Hoechst Aktiengesellschaft | Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use |
Non-Patent Citations (2)
Title |
---|
ARZNEIMITTELFORSCHUNG, vol. 24, no. 4, 1974, pages 494-499; U. JAHN et al.: "Wirkungsvergleich saurer Antiphlogistika im Bradykinin-, UV-Erythem- und Rattenpfotenödem-Test" * |
INDIAN JOURNAL OF CHEMISTRY, vol. 17B, May 1979, pages 472-477; V. VIRMANI et al.: "Chemistry of lactam acetals: Part II - Synthesis of pyrazoles & isoxazoles" * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0293220A3 (en) * | 1987-05-29 | 1990-07-11 | Ortho Pharmaceutical Corporation | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing |
EP0293221A2 (en) * | 1987-05-29 | 1988-11-30 | Ortho Pharmaceutical Corporation | Regioselective Synthesis of 1,5-Disubstituted Pyrazoles |
EP0293220A2 (en) * | 1987-05-29 | 1988-11-30 | Ortho Pharmaceutical Corporation | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing |
EP0293221A3 (en) * | 1987-05-29 | 1990-07-04 | Ortho Pharmaceutical Corporation | Regioselective synthesis of 1,5-disubstituted pyrazoles |
EP0388429A4 (en) * | 1987-11-13 | 1991-08-21 | Abbott Laboratories | Furan and pyrrole containing lipoxygenase inhibiting compounds |
US5112848A (en) * | 1987-11-13 | 1992-05-12 | Abbott Laboratories | Furan and pyrrole containing lipoxygenase inhibiting compounds |
EP0388429A1 (en) * | 1987-11-13 | 1990-09-26 | Abbott Laboratories | Furan and pyrrole containing lipoxygenase inhibiting compounds |
EP0320628A1 (en) * | 1987-11-13 | 1989-06-21 | Abbott Laboratories | Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase |
US5096919A (en) * | 1989-01-05 | 1992-03-17 | Ciba-Geigy Corporation | Pyrrolylphenyl-substituted hydroxamic acid derivatives |
US4960787A (en) * | 1989-02-06 | 1990-10-02 | Ciba-Geigy Corporation | Certain pyrrolyl-substituted hydroxamic acid derivatives |
EP0417449A1 (en) * | 1989-07-31 | 1991-03-20 | Bristol-Myers Squibb Company | Arylpyrazole derivatives as platelet aggregation inhibitors |
US5607958A (en) * | 1990-08-20 | 1997-03-04 | Sanofi | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them |
US5744491A (en) * | 1990-08-20 | 1998-04-28 | Sanofi | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them |
US5744493A (en) * | 1990-08-20 | 1998-04-28 | Sanofi | 3-amidopyrazole derivatives and pharmaceutical compositions containing them |
US5635526A (en) * | 1990-08-20 | 1997-06-03 | Sanofi | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them |
US5616592A (en) * | 1990-08-20 | 1997-04-01 | Sanofi | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them |
EP0480690A1 (en) * | 1990-10-10 | 1992-04-15 | Ciba-Geigy Ag | Aqueous ophthalmic microemulsions of tepoxalin |
EP0554829A2 (en) * | 1992-02-05 | 1993-08-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity |
EP0554829A3 (en) * | 1992-02-05 | 1994-06-08 | Fujisawa Pharmaceutical Co | Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity |
US5624941A (en) * | 1992-06-23 | 1997-04-29 | Sanofi | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
EP0576357A1 (en) * | 1992-06-23 | 1993-12-29 | Sanofi | Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them |
FR2692575A1 (en) * | 1992-06-23 | 1993-12-24 | Sanofi Elf | Novel pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them |
WO1996009292A1 (en) * | 1993-08-30 | 1996-03-28 | Ortho Pharmaceutical Corporation | 1,5-diphenyl-3-(n-hydroxycarbamoyloxyalkyl)pyrazoles |
WO1995013262A1 (en) * | 1993-11-12 | 1995-05-18 | Rhone-Poulenc Rorer Limited | Substituted phenyl compounds |
WO1996014302A1 (en) * | 1994-11-08 | 1996-05-17 | Eisai Co., Ltd. | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects |
WO1996038418A1 (en) * | 1995-06-02 | 1996-12-05 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6696477B2 (en) | 1995-06-02 | 2004-02-24 | Pharmacia Corporation | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6136839A (en) * | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
WO1999054314A1 (en) * | 1998-04-17 | 1999-10-28 | Boehringer Ingelheim Pharma Kg | Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
WO2004037793A1 (en) * | 2002-10-24 | 2004-05-06 | Wakamoto Pharmaceutical Co., Ltd. | Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase |
US9914705B2 (en) | 2008-04-25 | 2018-03-13 | Laboratorios Del Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
US9844516B2 (en) | 2010-02-04 | 2017-12-19 | Laboratorios De Dr. Esteve | Sigma ligands for use in the prevention and/or treatment of post-operative pain |
US9757358B2 (en) | 2010-02-04 | 2017-09-12 | Laboratorios Del Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US9782483B2 (en) | 2010-05-21 | 2017-10-10 | Laboratories Del Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
WO2011147910A1 (en) * | 2010-05-27 | 2011-12-01 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
US9181195B2 (en) | 2010-05-27 | 2015-11-10 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
RU2582338C2 (en) * | 2010-05-27 | 2016-04-27 | Лабораторьос Дель Др. Эстеве, С.А. | Pyrazole compounds as sigma receptor inhibitors |
AU2011257208B2 (en) * | 2010-05-27 | 2016-05-19 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
WO2011161615A1 (en) * | 2010-06-24 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
WO2011161645A1 (en) * | 2010-06-25 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
US9789115B2 (en) | 2010-08-03 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
US9789117B2 (en) | 2011-05-18 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
US9732038B2 (en) | 2012-06-14 | 2017-08-15 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of STAT3 |
EP2861562A4 (en) * | 2012-06-14 | 2015-12-16 | Mayo Foundation | Pyrazole derivatives as inhibitors of stat3 |
US10138208B2 (en) | 2012-06-14 | 2018-11-27 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of STAT3 |
US9931346B2 (en) | 2013-12-17 | 2018-04-03 | Laboratorios Del Dr. Esteve S.A. | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0248594B1 (en) | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | |
US5164381A (en) | Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same | |
US5051518A (en) | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides | |
EP0293220B1 (en) | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | |
US6083969A (en) | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents | |
US4743587A (en) | Hydroxamic acid based collagenase inhibitors | |
FI71929C (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ETERFOERENINGAR SAMT VID DERAS FRAMSTAELLNING ANVAENDBARA MELLANPRODUKTER. | |
US4861798A (en) | Lipoxygenase inhibitory compounds | |
US5242940A (en) | Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same | |
US5110831A (en) | Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors | |
EP0538416B1 (en) | Substituted monocyclic aryl compounds exhibiting selective leukotriene b 4 antagonist activity | |
US4731382A (en) | Lipoxygenase inhibitory phenylalkanohydroxamic acids | |
US4742058A (en) | Polyprenyl compound, process for the production thereof and drug containing the same | |
AU630261B2 (en) | Novel 2-substituted 4-(3-alkyl-5-tert.-butyl-4-hydroxyphenyl)thiazoles, processes for their preparation, pharmaceuticals containing them and their use | |
HU203722B (en) | Process for producing substituted hydroxyamines and pharmaceutical compositions containing them | |
US4898952A (en) | Regioselective synthesis of a 1,5-disubstituted pyrazole | |
US4230719A (en) | Novel 2-[4-(3-methyl-2-thienyl)phenyl]propionic acid and pharmaceutically acceptable salt thereof and method for treating symptoms of inflammation and pain | |
WO1986007357A3 (en) | Cyclopentapyrazole and tetrahydroindazole compounds | |
US4782085A (en) | Arylhydroxamates and use thereof in treating allergies | |
GB2132618A (en) | Dibenzocycloheptenylidenes | |
JP2518497B2 (en) | Antilipemic agent | |
EP0293221A2 (en) | Regioselective Synthesis of 1,5-Disubstituted Pyrazoles | |
EP0087858A1 (en) | New chromanone compounds and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19890419 |
|
17Q | First examination report despatched |
Effective date: 19901113 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 97660 Country of ref document: AT Date of ref document: 19931215 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 3788244 Country of ref document: DE Date of ref document: 19940105 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3009905 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 97660 Country of ref document: AT Kind code of ref document: T |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
EPTA | Lu: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2059377 Country of ref document: ES Kind code of ref document: T3 |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 87304720.3 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP Free format text: PRODUCT NAME: TEPOXALIN; REGISTRATION NO/DATE: EU/2/00/028/001 20010313 Spc suppl protection certif: 01C0034 Filing date: 20010911 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCF Free format text: 0190030-7, 20010313 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFF Free format text: GBCTFFSPC/GB2001/038, 20010907 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CR Free format text: FRCR 2001C0034, 20010911 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: CCP Free format text: LUCCP 90829, EXPIRES: 20120528 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: ESZA Free format text: PRODUCT NAME: TEPOXALIN UND DESSEN PHARMAZEUTISCH VERTR?GLICHE SALZE Spc suppl protection certif: SZ 23/2001 Filing date: 20010910 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: AC1 Free format text: NLAC1 300057, 20010910 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EEZF Spc suppl protection certif: SZ 23/2001 Filing date: 20010910 Extension date: 20120528 Effective date: 20011105 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: KC1 Free format text: NLKC1 300057, 20070528, EXPIRES: 20120527 |
|
CCPV | Be: grant of a complementary protection certificate |
Free format text: 2001C/034, EXPIRES: 20120528 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CY Free format text: FRCY 01C0034, 20010911, EXPIRES: 20120527 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: CTFG Free format text: GBCTFGSPC/GB01/038: 20020516, EXPIRES: 20120527 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: SPCG Free format text: 0190030-7 Spc suppl protection certif: 0190030-7 Ref country code: SE Ref legal event code: SPCG Free format text: 0190030-7, 20010313 Spc suppl protection certif: 0190030-7 Filing date: 20010313 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20060413 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20060503 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20060505 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20060511 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20060515 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20060524 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20060525 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20060530 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20060531 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20060601 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20060621 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20060712 Year of fee payment: 20 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20070528 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Ref country code: GB Ref legal event code: CTFE Free format text: SPC/GB01/038: 20070528, EXPIRES: 20120527 Spc suppl protection certif: SPC/GB01/038 Filing date: 20070528 Expiry date: 20120527 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20070528 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: EELA Ref document number: 97660 Country of ref document: AT Kind code of ref document: T |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20070527 |
|
BE20 | Be: patent expired |
Owner name: *ORTHO PHARMACEUTICAL CORP. Effective date: 20070528 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120509 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: CCRE Owner name: *ORTHO PHARMACEUTICAL CORP. Free format text: PRODUCT NAME: TEPOXALIN; REGISTRATION NO/DATE: EU/2/00/028/001 20010313 Spc suppl protection certif: 2001C/034 Filing date: 20010911 Expiry date: 20070528 Extension date: 20120528 Effective date: 20120528 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: SPCE Free format text: PRODUCT NAME: TEPOXALIN; REGISTERED: UK EU/2/00/028/001 20010313; UK EU/2/00/028/002 20010313; UK EU/2/00/028/003 20010313; UK EU/2/00/028/004 20010313; UK EU/2/00/028/005 20010313; UK EU/2/00/028/006 20010313; UK EU/2/00/028/007 20010313; UK EU/2/00/028/008 20010313 Spc suppl protection certif: SPC/GB01/038 Filing date: 20010907 Expiry date: 20070528 Extension date: 20120527 Ref country code: NL Ref legal event code: SPCX Free format text: PRODUCT NAME: TEPOXALINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/2/00/028/001 - EU/2/00/028/008 20010313 Spc suppl protection certif: C300057 Filing date: 20010910 Expiry date: 20070528 Extension date: 20120527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20070529 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: SPCX Ref document number: 97660 Country of ref document: AT Kind code of ref document: T Free format text: PRODUCT NAME: TEPOXALIN UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE; REGISTRATION NO/DATE: EU/2/00/028/001- EU/2/00/028/008 20010313 Spc suppl protection certif: 23/2001 Filing date: 20010910 Expiry date: 20070528 Extension date: 20120528 Effective date: 20120528 |